Respiratory tract neoplasm
MONDO:0020641A benign or malignant, primary or metastatic neoplasm involving the respiratory tract.
Also known as: neoplasm of respiratory tract, neoplasm of the respiratory tract, neoplasm, respiratory tract, neoplasms, respiratory tract, respiratory system neoplasm, respiratory tract neoplasm, respiratory tract tumor, respiratory tract tumour
5590 clinical trials for this condition and its sub-types, 32 tagged with Respiratory tract neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Respiratory tract neoplasm
-
Lung neoplasm 1,371 trials · 4,046 incl. sub-types
10 sub-types
- Lung cancer 1,212 trials · 3,948 incl. sub-types Sub-types →
- Lung neuroendocrine neoplasm 21 trials · 540 incl. sub-types Sub-types →
- Lung benign neoplasm 1 trial · 2 incl. sub-types Sub-types →
- Lung PEComa 0 trials · 1 incl. sub-types Sub-types →
- Pulmonary sulcus neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Langerhans cell histiocytosis specific to adulthood 0 trials Sub-types →
- Fibroma of lung 0 trials
- Hamartoma of lung 0 trials Sub-types →
- Lung germ cell tumor 0 trials
- Lung hilum neoplasm 0 trials Sub-types →
-
Nasopharyngeal neoplasm 37 trials · 226 incl. sub-types
3 sub-types
- Malignant tumor of nasopharynx 9 trials · 214 incl. sub-types Sub-types →
- Benign neoplasm of nasopharynx 0 trials
- Nasopharyngeal teratoma 0 trials
-
Laryngeal neoplasm 72 trials · 138 incl. sub-types
6 sub-types
- Larynx cancer 41 trials · 125 incl. sub-types Sub-types →
- Glottis neoplasm 3 trials · 12 incl. sub-types Sub-types →
- Supraglottis neoplasm 0 trials · 3 incl. sub-types Sub-types →
- Benign laryngeal neoplasm 1 trial · 2 incl. sub-types Sub-types →
- Subglottis neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Laryngeal neuroendocrine neoplasm 0 trials Sub-types →
-
Pleural neoplasm 5 trials · 97 incl. sub-types
5 sub-types
- Pleural mesothelioma 28 trials · 86 incl. sub-types Sub-types →
- Pleural cancer 9 trials · 83 incl. sub-types Sub-types →
- Benign neoplasm of pleura 0 trials Sub-types →
- Neurilemmoma of the pleura 0 trials
- Pleural solitary fibrous tumor 0 trials Sub-types →
-
Bronchial neoplasm 20 trials · 38 incl. sub-types
5 sub-types
- Bronchus cancer 3 trials · 26 incl. sub-types Sub-types →
- Bronchial endocrine tumor 4 trials
- Bronchus adenoma 0 trials Sub-types →
- Endobronchial leiomyoma 0 trials
- Endobronchial lipoma 0 trials
-
Nasal cavity neoplasm 1 trial · 15 incl. sub-types
3 sub-types
- Nasal cavity cancer 5 trials · 14 incl. sub-types Sub-types →
- Benign neoplasm of nasal cavity 1 trial Sub-types →
- Nasal cavity inverting papilloma 0 trials
-
SMARCA4-deficient sarcoma of thorax 8 trials
-
Trachea neoplasm 2 trials · 5 incl. sub-types
2 sub-types
- Benign neoplasm of trachea 0 trials · 2 incl. sub-types Sub-types →
- Tracheal cancer 0 trials · 1 incl. sub-types Sub-types →
Most studied deeper sub-types
Showing the 400 most recently updated of 902 trials in this tab.
-
Can immunotherapy help patients keep their voice box?
Cure CompletedThis trial tests whether a combination of the immunotherapy drug pembrolizumab, chemotherapy, and radiation can control advanced larynx cancer while preserving the voice box. Adults with stage III or IV larynx cancer who are candidates for organ preservation receive three cycles …
Phase 2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Cure
Last updated Aug 29, 2026 00:00 UTC
-
Can a cancer vaccine train the body to fight advanced tumors?
Cure CompletedThis phase 1 trial is testing an experimental therapeutic cancer vaccine called AST-021p in people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if the vaccine is safe and can trigger an immune response against the cancer. Participan…
Phase 1 • Sponsor: Aston Sci. Inc. • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Can a Cell-Derived vaccine hold lung cancer at bay?
Vaccine CompletedThis phase 2 trial tests whether a vaccine made from immune cell-derived exosomes can slow cancer growth in people with advanced non-small cell lung cancer who have responded to initial chemotherapy. Participants receive low-dose cyclophosphamide followed by weekly injections of …
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Vaccine
Last updated Aug 19, 2026 00:00 UTC
-
New hope for tough lung cancer: LAGOON trial tests powerful drug combo
Disease control CompletedThis study tested two new treatments for people with small cell lung cancer that came back after initial chemotherapy. The experimental drugs, lurbinectedin alone or with irinotecan, were compared to standard treatments (topotecan or irinotecan). The goal was to see if the new op…
Phase 3 • Sponsor: PharmaMar • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Lung cancer combo shows promise in Second-Line trial
Disease control CompletedThis phase 2 study tested whether adding the targeted drug erlotinib to standard chemotherapy (docetaxel) works better than chemotherapy alone for people with advanced non-small cell lung cancer whose first treatment stopped working. 156 participants were randomly assigned to one…
Phase 2 • Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
Disease control CompletedResearchers are running a Phase I trial of HG146, an experimental oral drug, in adults with advanced solid tumors or lymphoma that have worsened despite standard treatments. The study first tests HG146 alone to find a safe dose, then tests it combined with a PD-(L)1 antibody, a t…
Phase 1 • Sponsor: HitGen Inc. • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Can a lighter chemo punch still knock out lung cancer when paired with immunotherapy?
Disease control CompletedThis completed Phase 4 trial tested two different doses of chemotherapy (standard and low-dose) combined with the immunotherapy drug Sintilimab in 20 people with advanced squamous non-small cell lung cancer. The goal was to see if the lower-dose combination could shrink tumors an…
Phase 2 • Sponsor: People's Hospital of Quzhou • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Double immunotherapy attack shows promise in tough lung cancer
Disease control CompletedThis Phase 3 study tests whether adding tiragolumab (an experimental immunotherapy) to the standard combination of atezolizumab plus chemotherapy can help people with untreated, widespread small cell lung cancer live longer without their disease worsening. About 123 participants …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control CompletedThis study tests a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The two drugs, LY3295668 and osimertinib, work by blocking enzymes that help cancer cells grow. The goal is to find the safest dose and see if…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Elderly cancer patients may benefit from geriatric support
Disease control CompletedThis study looked at whether a special care plan led by a geriatrician and a nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…
Sponsor: Institut Bergonié • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a vitamin supplement make chemotherapy hit mesothelioma harder?
Disease control CompletedResearchers are testing whether adding vitamin B12 to standard chemotherapy helps people with pleural mesothelioma that cannot be removed by surgery. The trial gives participants pemetrexed and cisplatin, two chemotherapy drugs that block tumor cell growth in different ways, alon…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody GNR-051 tested for safety in Hard-to-Treat cancers
Disease control CompletedResearchers are testing an experimental immunotherapy called GNR-051 in adults with advanced lung cancer, kidney cancer, or melanoma that has returned or not responded to other treatments. The Phase 1 trial aims to find the highest dose people can tolerate and to track side effec…
Phase 1 • Sponsor: AO GENERIUM • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to boost cancer treatment
Disease control CompletedThis early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a chemotherapy) is safe and tolerable for people with advanced solid tumors that no longer respond to standard treatments. The study included 47 adults and children aged 12 and older. Researchers aimed…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New cocktail of three drugs tested for tough bladder cancers
Disease control CompletedThis early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can zapping brain tumors boost immunotherapy against lung cancer?
Disease control CompletedResearchers are testing whether adding brain radiotherapy to PD-1/PD-L1 inhibitors and chemotherapy helps people with untreated stage IV non-small cell lung cancer that has spread to the brain. The trial enrolls about 40 adults whose tumors lack common driver mutations and whose …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo immunotherapy drug enters human trials for 18 cancers
Disease control CompletedThis early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…
Phase 1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat lung cancer
Disease control CompletedThis study tests a new drug, Tuvusertib, combined with an immunotherapy called Cemiplimab in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has worsened after prior treatments. The trial aims to see if the combination can shrink tumors and …
Phase 1/2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Higher radiation dose vs standard: which fights small cell lung cancer better?
Disease control CompletedResearchers are comparing two doses of chest radiation therapy, 45 Gy and 70 Gy, in people with limited-stage small cell lung cancer. All participants also receive chemotherapy with cisplatin or carboplatin plus etoposide. The trial measures overall survival to see whether the hi…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase 1/2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New Non-Invasive lung nodule marking method tested in small trial
Disease control CompletedThis pilot study tested a new, non-invasive way to locate multiple small lung nodules (under 20 mm) before surgery, comparing it to the standard CT-guided needle method. Forty people with early-stage lung cancer took part. The goal was to see if the new method could help surgeons…
Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can an Antibody-Drug conjugate crack resistant EGFR lung cancer?
Disease control CompletedResearchers are testing an experimental drug called MRG003 in adults with EGFR-positive advanced non-small cell lung cancer that has worsened after at least two standard treatments. The trial enrolls about 87 participants across multiple sites and gives MRG003 intravenously as a …
Phase 2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for HER2 cancers: targeted drug shows promise in Mid-Stage trial
Disease control CompletedThis phase 2 trial is testing a drug called ado-trastuzumab emtansine (Kadcyla) in 131 adults with advanced solid tumors that have a specific HER2 gene change. The drug combines an antibody that targets HER2 with a chemotherapy agent, aiming to deliver treatment directly to cance…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can cutting arginine from the diet starve solid tumors?
Disease control CompletedThis phase 1 trial is testing whether a diet that severely limits arginine—an amino acid some tumors depend on—is safe and might help control solid tumors. About 25 adults with solid tumors will follow a specially designed low-arginine liquid diet for two 3-week cycles while cont…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Lung surgery without a breathing tube: a gentler path to recovery?
Disease control CompletedThis trial tests whether removing lung nodules with non-intubated video-assisted thoracic surgery, which avoids a breathing tube and ventilator, helps patients recover faster and feel better than traditional intubated surgery. Researchers will compare symptom burden, quality of l…
Sponsor: Fudan University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug combo revive the immune System's attack on resistant cancers?
Disease control CompletedThis phase 2 trial tests whether adding an experimental drug called pixatimod to the immunotherapy nivolumab can shrink tumors in people with advanced melanoma, non-small cell lung cancer, or colorectal cancer that has stopped responding to prior treatment. One group with colorec…
Phase 2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New combo aims to outsmart resistant lung cancer
Disease control CompletedThis phase 3 trial tested whether a combination of sitravatinib (a targeted drug) and nivolumab (an immunotherapy) works better than docetaxel (standard chemo) for people with advanced non-squamous non-small cell lung cancer that got worse after platinum chemo and checkpoint inhi…
Phase 3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can immunotherapy outperform chemotherapy for lung cancer?
Disease control CompletedThis trial studies people with advanced non-small cell lung cancer who have already tried platinum-based chemotherapy. Researchers compare those who receive immunotherapy with those who receive standard chemotherapy as a second-line treatment. The goal is to see which approach he…
Sponsor: Myung-Ju Ahn • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug SG1827 enters first human tests for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…
Phase 1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new pill boost Immunotherapy's power against advanced tumors?
Disease control CompletedThis trial tests an experimental drug called FLX475, given alone or with the immunotherapy pembrolizumab, in people with advanced cancers that have not responded to standard treatments. The study aims to find the safest dose and to see whether the combination can shrink tumors. P…
Phase 1/2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can steroid shots shield salivary glands from radiation damage?
Disease control CompletedThis pilot study tests whether injecting a corticosteroid called dexamethasone directly into the salivary glands can prevent dry mouth in people receiving radiation therapy for head and neck cancer. Researchers will enroll 10 adults with certain types of throat cancer who are sch…
Phase 1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Fiber fuel: could a High-Fiber diet boost cancer treatment?
Disease control CompletedThis study looks at whether eating a high-fiber diet (over 21 grams per day) can change gut bacteria and improve the immune system's ability to fight solid tumors like colorectal cancer. About 25 adults with solid tumors will follow this diet to see if it is safe and helps with t…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new antibody help the immune system fight Hard-to-Treat tumors?
Disease control CompletedThis trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…
Phase 1/2 • Sponsor: Sensei Biotherapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can radiation turn tumors into targets for immunotherapy?
Disease control CompletedThis trial tests whether combining the immunotherapy drug atezolizumab with precise, high-dose radiation (SABR) can better control metastatic cancers, including colorectal, lung, kidney, and sarcoma. The idea is that radiation may make tumors more visible to the immune system, wh…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can an experimental drug shrink advanced solid tumors?
Disease control CompletedThis phase 1 trial tests an experimental drug called MRG003 in people with advanced solid tumors, including colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. The study aims to find a safe dose and to see whether the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail shows promise for EGFR lung cancer
Disease control CompletedThis Phase 2 trial tests a combination of three drugs—amivantamab, lazertinib, and pemetrexed—as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. The study includes 54 participants across Latin America. Researchers want to see if this comb…
Phase 2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Lung cancer drug under watch: new study tracks Real-World safety
Disease control CompletedThis study is monitoring the safety and side effects of the drug XALKORI in people with a certain type of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not taken this drug before. About 97 participants are being followed to see how well the drug works a…
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo aims to extend life in advanced lung cancer
Disease control CompletedThis phase 3 trial tests whether a new drug combination (MK-7684A) plus chemoradiotherapy helps people with stage III non-small cell lung cancer live longer than the current standard treatment. About 611 participants will receive either the new combo or durvalumab. The study is a…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug sh…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo shows promise in halting advanced cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs, vandetanib and everolimus, in 151 people with advanced or metastatic cancer that had stopped responding to standard treatments. The goal was to find the safest dose and see if the combination could slow or stop cancer grow…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested whether giving the immunotherapy drug durvalumab alongside radiation works better than the standard cetuximab plus radiation for people with advanced head and neck cancer who cannot take the usual chemotherapy drug cisplatin. A total of 196 adults took part. The…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 150 adults with certain…
Phase 1 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New combo shows promise for tough lung cancer
Disease control CompletedThis phase 2 study tested a combination of two drugs—ivonescimab (AK112) and irinotecan liposome—in 60 people with extensive-stage small-cell lung cancer whose disease had worsened after standard first-line therapy. The goal was to see if the combo could slow cancer growth and sh…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new chemo combo outsmart small cell lung cancer?
Disease control CompletedThis trial is testing whether a new form of chemotherapy called PLX038 can be safely combined with the PARP inhibitor rucaparib to shrink tumors in people with small cell lung cancer, small cell cancer outside the lungs, or other solid tumors. The study has two parts: first, find…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a drug duo outsmart EGFR-Mutant lung cancer?
Disease control CompletedThis trial investigates whether combining two targeted drugs—erlotinib and bevacizumab—can help people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see if the combination extends the time before the cancer grows or spreads. Participant…
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a targeted drug tame HER2-Mutant lung cancer?
Disease control CompletedThis phase 2 trial investigates whether afatinib, an oral targeted therapy, can control advanced non-small cell lung cancer (NSCLC) that carries a specific HER2 exon 20 mutation. Participants have already received prior chemotherapy and have stage IIIB or IV disease. The study me…
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Blood test may predict which lung cancer drug works best
Disease control CompletedThis trial is testing whether a blood test called VeriStrat can help choose between two drugs for people with advanced squamous non-small cell lung cancer that has progressed after initial chemotherapy. Participants are grouped by their VeriStrat result (good or poor) and then ra…
Phase 3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New combo therapy shows promise for Drug-Resistant lung cancer
Disease control CompletedThis study tested whether adding bevacizumab to osimertinib helps people with advanced non-small cell lung cancer that has a specific genetic change (EGFR and T790M mutations). 155 adults who had already tried other treatments took part. The main goal was to see if the combinatio…
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new drug formulation shrink Hard-to-Treat neuroendocrine tumors?
Disease control CompletedThis phase 2 trial is testing an investigational drug called nab-sirolimus in people with advanced neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas. Participants must have had up to two prior lines of therapy (excluding somatostatin analogs) and must …
Phase 2 • Sponsor: Aadi Bioscience, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can an immune booster make standard lung cancer treatment more effective?
Disease control CompletedThis trial is investigating whether adding the immunotherapy drug nivolumab to the usual chemotherapy and radiation can improve outcomes for people with stage III non-small cell lung cancer. The study will measure how well the combination works and how tolerable the side effects …
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can immunotherapy extend remission in Limited-Stage lung cancer?
Disease control CompletedThis trial is investigating whether adding two immunotherapy drugs, nivolumab and ipilimumab, after standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. Even though initial treatment often works well, the cancer frequently returns within …
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can an immunotherapy drug outperform chemotherapy for mesothelioma?
Disease control CompletedThis trial compares two treatments for people with advanced malignant pleural mesothelioma, a cancer of the lining of the lungs, that has progressed after initial chemotherapy. Half of the participants receive pembrolizumab, an immunotherapy that helps the immune system fight can…
Phase 3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a more intense radiation schedule outperform Chemo-Radiation for head and neck cancer?
Disease control CompletedThis trial tests two aggressive radiation therapy schedules for people with advanced head and neck cancer that cannot be removed with surgery. One approach uses a very intense radiation schedule combined with chemotherapy, while the other uses a very accelerated radiation schedul…
Phase 2/3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New combo therapy aims to keep lung cancer from returning after surgery
Disease control CompletedThis study tests the safety of combining the targeted drug alectinib with chemotherapy in people who have had surgery for a specific type of lung cancer (ALK-positive non-small cell lung cancer). The 11 participants received up to four cycles of the drug combo after their tumor w…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New oral drug targets Cancer's growth engine in advanced tumours
Disease control CompletedThis trial investigates an experimental oral drug, LY3143921 hydrate, which blocks a protein called Cdc7 that cancer cells need to divide. It is being tested in adults with advanced solid tumours, including colorectal, ovarian, lung, and pancreatic cancers, that have not responde…
Phase 1 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can an Immune-Boosting antibody extend life in advanced lung cancer?
Disease control CompletedThis trial is investigating whether adding an experimental antibody called CS1001 to standard chemotherapy can help people with stage IV non-small cell lung cancer. The study compares the combination against chemotherapy alone in patients who have not yet received treatment for a…
Phase 3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New combo therapy for lung cancer passes first safety test
Disease control CompletedThis early-phase trial tested the drug everolimus (RAD001) alongside radiation therapy in 26 people with advanced non-small cell lung cancer that could not be surgically removed. The goal was to find a safe dose and check for side effects. Participants received everolimus weekly …
Phase 1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can heat zap lung tumors without surgery?
Disease control CompletedThis trial tests whether radiofrequency ablation—a procedure that uses heat to destroy cancer cells—can effectively treat lung tumors that cannot be removed with surgery. The study includes people with primary lung cancer or lung metastases, with up to five tumors each no larger …
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can an immune booster before surgery beat lung cancer?
Disease control CompletedThis trial is testing whether giving the immunotherapy drug atezolizumab before surgery can help people with early-stage non-small cell lung cancer. The study includes adults with stage IB to IIIA (non-N2) disease who are eligible for surgery. Participants receive one dose of ate…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new immunotherapy combo outsmart advanced lung cancer?
Disease control CompletedThis phase II trial is testing whether the immunotherapy drug tislelizumab can help control locally advanced non-small cell lung cancer when given after radiation therapy or sequential chemoradiation. The study enrolls people with stage III lung cancer who cannot tolerate the sta…
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill shows promise for rare lung cancer mutation in early trial
Disease control CompletedThis early-phase study tests a new oral drug, furmonertinib, in 30 people with advanced non-small cell lung cancer that has a specific EGFR exon 20 insertion mutation. Some participants have already tried other treatments, while others are newly diagnosed. The goal is to see if t…
Phase 1 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New cocktail of drugs aims to tackle tough lung cancer
Disease control CompletedThis phase 2 trial tests whether adding experimental drugs (MK-4830, boserolimab, or lenvatinib) to the standard combination of pembrolizumab and chemotherapy can improve outcomes for people with extensive-stage small cell lung cancer. Participants receive one of these new combin…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Lung cancer trial: adding chemo to targeted pill may buy more time
Disease control CompletedThis Phase 2 trial tests whether adding chemotherapy (carboplatin and pemetrexed) to the targeted drug osimertinib works better than osimertinib alone for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The study enrolls 80 patients w…
Phase 2 • Sponsor: Beijing Cancer Prevention & Treatment Society • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a simple shot replace IV drips for lung cancer immunotherapy?
Disease control CompletedThis early-stage trial is testing whether an immunotherapy drug called tislelizumab can be given as a simple injection under the skin instead of through an IV drip for people with advanced non-small cell lung cancer. The study will compare how well the body absorbs the drug in bo…
Phase 1 • Sponsor: BeiGene • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant lung cancer?
Disease control CompletedThis early-phase trial is testing whether adding an experimental drug called alisertib to the standard treatment osimertinib can help people with stage IV EGFR-mutant lung cancer. The study aims to find the safest dose of alisertib when given with osimertinib and to see how the c…
Phase 1 • Sponsor: Collin Blakely • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a modified herpes virus turn the tide against advanced cancer?
Disease control CompletedThis early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembroliz…
Phase 1/2 • Sponsor: Binhui Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new drug tame advanced solid tumors?
Disease control CompletedThis early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…
Phase 1 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can AI-Guided radiation tame lung tumors without the burn?
Disease control CompletedThis trial is testing a new radiation technique called CT-STAR for people with early-stage non-small cell lung cancer located near the center of the chest, where treatment is tricky. The approach uses a machine that takes CT images during each session and adapts the radiation pla…
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can an immunotherapy drug revive the fight against resistant lung cancer?
Disease control CompletedThis trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy can help people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation and have stopped responding to TKI targeted therapy. About 440 participants will be…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can an ancient herbal tonic boost modern immunotherapy against lung cancer?
Disease control CompletedThis trial is testing whether adding the traditional herbal remedy Bojungikki-tang to the immunotherapy drug pembrolizumab can help people with advanced non-small cell lung cancer. The study includes adults with stage IV disease whose tumors are PD-L1 positive and who have no EGF…
Phase 2 • Sponsor: Korea Institute of Oriental Medicine • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill targets tough cancers in early human trial
Disease control CompletedThis early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…
Phase 1/2 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
One pill before radiation: a new shield for bones?
Disease control CompletedThis trial tests whether a single dose of risedronate, a bone-strengthening drug, given before stereotactic body radiation therapy (SBRT) for peripheral lung tumors can prevent the rapid bone loss that radiation can cause in nearby ribs. Adults with lung tumors within 2 cm of the…
Phase 2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can less radiation be safer without sacrificing cancer control?
Disease control CompletedThis study tested whether giving lower doses of radiation after surgery for head and neck cancer could reduce long-term side effects like dry mouth and trouble swallowing, while still keeping the cancer from coming back. About 200 patients with certain stages of oral, throat, or …
Phase 2 • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug duo shows promise for tough lung cancer
Disease control CompletedThis completed Phase 1/2 trial tested a combination of two drugs, amivantamab and docetaxel, in 12 people with advanced non-small cell lung cancer that had spread. The goal was to find a safe dose and see if the combo could shrink tumors. The study focused on patients whose cance…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart advanced cancers?
Disease control CompletedThis trial is testing whether adding an experimental drug called HBI-8000 to the immunotherapy nivolumab can safely control advanced melanoma, kidney cancer, and non-small cell lung cancer. The study enrolls adults whose cancers have not responded to prior treatments. Researchers…
Phase 1/2 • Sponsor: HUYABIO International, LLC. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat cancers? an early trial seeks answers
Disease control CompletedThis early-phase trial is testing an experimental drug called SPYK04 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for early signs that SPYK…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New combo therapy shows promise for hard-to-treat lung cancer
Disease control CompletedThis study tested a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The trial enrolled 95 adults and gave them two different combinations of immunotherapy (atezolizum…
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
Disease control CompletedThis phase 2 trial tests whether adding lenvatinib to a standard chemotherapy-plus-immunotherapy regimen can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation. Participants will receive lenvatinib capsules daily along …
Phase 2 • Sponsor: Juntendo University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can an RNAi drug shrink Hard-to-Treat tumors?
Disease control CompletedThis phase 1 trial is testing an experimental drug called STP707 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see whether the drug can slow or shrink tumors. Participants receive STP707 b…
Phase 1 • Sponsor: Sirnaomics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Lung cancer drug shows promise against brain metastases
Disease control CompletedThis study tested the drug osimertinib (Tagrisso) in 73 patients with a specific type of lung cancer that had spread to the lining of the brain and spinal cord (leptomeningeal metastases). Patients took one 80 mg tablet daily. The goal was to see if the drug could improve overall…
Phase 2 • Sponsor: Sehhoon Park • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase 1/2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a Chest-Injected drug drain Cancer's fluid trap?
Disease control CompletedThis trial tests an experimental drug, RSO-021, given directly into the chest cavity of people with malignant pleural effusion—a buildup of fluid around the lungs caused by advanced solid tumors or mesothelioma. The study aims to find a safe dose and check for early signs that th…
Phase 1/2 • Sponsor: RS Oncology LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can an immunotherapy combo shrink lung tumors before surgery? a phase 3 trial aims to find out.
Disease control CompletedThis phase 3 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with stage II-III non-small cell lung cancer. Participants receive either toripalimab plus chemotherapy or a placebo plus chemotherap…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new infusion drug tame advanced solid tumors?
Disease control CompletedThis early-phase trial is testing an experimental drug called SM3321 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose. Participants receive SM3321 as a we…
Phase 1 • Sponsor: Beijing StarMab Biomed Technology Ltd • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo therapy shows promise for rare lung cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug atezolizumab to standard treatment (bevacizumab plus chemotherapy) helps people with advanced malignant pleural mesothelioma live longer. The trial involved 400 adults whose cancer could not be removed by surgery. Researcher…
Phase 3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can an immunotherapy cocktail shrink inoperable lung tumors?
Disease control CompletedThis phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy and radiation can help people with stage III non-small cell lung cancer that cannot be surgically removed. About 50 participants will receive the combination treatment, and …
Phase 2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Experimental drug JS015 takes first steps against advanced solid tumors
Disease control CompletedThis early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will recei…
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Radiation and immunotherapy join forces against early lung cancer
Disease control CompletedThis trial investigates whether combining stereotactic body radiotherapy (SBRT), a precise form of radiation, with the immunotherapy drug nivolumab is safe and tolerable for people with early-stage non-small cell lung cancer. Participants receive SBRT followed by nivolumab infusi…
Phase 1/2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Targeted drug hunts down cancer cells in advanced bladder cancer trial
Disease control CompletedThis trial tests an experimental drug called enfortumab vedotin, which is designed to seek out and destroy cancer cells that have a specific protein called Nectin-4 on their surface. The study includes people with metastatic urothelial cancer (a type of bladder cancer) and other …
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug SHR-7367 takes first step against advanced cancers
Disease control CompletedThis early-stage trial tests an experimental drug called SHR-7367 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 22 participants will …
Phase 1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Shrinking lung tumors before surgery: targeted drugs show promise for rare cancer type
Disease control CompletedThis study looks at whether giving targeted drugs called ROS1 inhibitors before surgery can help people with a rare form of lung cancer. The drugs, entrectinib or crizotinib, are designed to attack cancer cells with a specific genetic change. Researchers will check how much the t…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental pill takes on advanced cancers alongside immunotherapy
Disease control CompletedThis early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a cheaper copy of keytruda work just as well against cancer?
Disease control CompletedThis study tests whether a new drug called RPH-075, a biosimilar of pembrolizumab (Keytruda), works as well as the original in people with skin melanoma, lung cancer, or head and neck cancer. Participants receive a single dose of either RPH-075 or Keytruda, and researchers compar…
Phase 1 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
Disease control CompletedThis phase 2 trial tests the experimental drug LDK378 in adults with advanced non-small cell lung cancer that has a specific genetic change called a ROS1 rearrangement. Participants must have already received at least one platinum-based chemotherapy and their cancer must have pro…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Lab-Made immune protein takes on advanced cancers in first human test
Disease control CompletedThis study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Immunotherapy combo targets rare, aggressive lung cancer
Disease control CompletedThis trial investigates whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (carboplatin and etoposide) helps people with a rare and aggressive lung cancer called large cell neuroendocrine carcinoma (LCNEC). The study enrolls adults with advanc…
Phase 1 • Sponsor: Oncology Center of Biochemical Education And Research • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can an arthritis drug help fight lung cancer?
Disease control CompletedThis phase II trial tests whether adding canakinumab, an anti-inflammatory drug, to standard chemoradiation and immunotherapy (durvalumab) helps control locally advanced non-small cell lung cancer. About 41 participants will receive the combination to see if it improves progressi…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Personalized vaccine plus immunotherapy shows promise for tough lung cancer
Disease control CompletedThis study tested whether adding a personalized dendritic cell vaccine to the immunotherapy drug atezolizumab could help people with extensive-stage small cell lung cancer stay stable longer after initial chemotherapy. Twenty participants received standard chemo plus atezolizumab…
Phase 1/2 • Sponsor: Instituto Oncológico Dr Rosell • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill takes on tough cancers: first human trial begins
Disease control CompletedThis early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…
Phase 1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Immunotherapy shot could replace IV drip for advanced head and neck cancer
Disease control CompletedThis phase I study is testing a subcutaneous (under the skin) injection of toripalimab, an immunotherapy drug, for people with advanced nasopharyngeal carcinoma. The trial compares the new injection to the standard intravenous (IV) version, looking at safety, tolerability, and ho…
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Breathing-Guided radiation aims to protect healthy lung tissue
Disease control CompletedThis study investigates whether 4DCT scans—which capture how a tumor moves when a person breathes—can be used to design radiation plans that avoid high-functioning healthy lung tissue. People with non-small cell lung cancer who are scheduled for radiation therapy may join. The go…
Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immunotherapy combo shows promise in advanced lung cancer trial
Disease control CompletedThis phase 3 study tested whether adding the immunotherapy drug retifanlimab (INCMGA00012) to standard platinum-based chemotherapy helps people with advanced non-small cell lung cancer live longer. The trial enrolled 583 patients who had not received prior treatment for metastati…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
AI-Powered navigation aims to pinpoint tiny lung nodules during surgery
Disease control CompletedThis study tests a device called the LungVision system, which uses artificial intelligence to help surgeons locate small lung nodules during minimally invasive surgery. The system combines CT scans with live X-ray images to guide a tool to the nodule, then injects a dye to mark i…
Sponsor: Tri-Service General Hospital (TSGH) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Double-Drug attack on tough lung cancer mutation
Disease control CompletedThis study tests whether combining two targeted drugs, avutometinib and adagrasib, can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried a KRAS G12C inhibitor and seen their c…
Phase 1/2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase 1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase 1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Lighter suction after lung surgery may speed recovery
Disease control CompletedThis trial tests whether a gentler suction level (-2 cmH2O) on chest tubes after keyhole lung cancer surgery works as well as the standard stronger suction (-10 cmH2O). The goal is to see which setting allows tubes to be removed sooner and causes fewer complications. About 230 ad…
Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug shrinks tumors in patients with rare gene mutation
Disease control CompletedThis study tested the drug larotrectinib in 215 adults with various solid cancers that have a specific change in the NTRK gene. The drug is taken orally and works by blocking the action of the altered gene. The main goal was to see how many patients had their tumors shrink or dis…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Old chemo drug gets new partner in fight against lung cancer
Disease control CompletedThis phase II trial tests whether a low-dose, frequent schedule of the chemotherapy drug vinorelbine, taken orally, can boost the effects of the immunotherapy atezolizumab in people with stage IV non-small cell lung cancer. The study enrolls adults whose cancer has progressed aft…
Phase 2 • Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to keep lung cancer at bay after chemo
Disease control CompletedThis phase 3 trial tested whether adding niraparib (a drug that interferes with cancer cell repair) to pembrolizumab (an immunotherapy) helps keep advanced non-small cell lung cancer from progressing. The study enrolled 666 adults whose cancer had stabilized or shrunk after initi…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase 1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail of immune drugs shows promise in lung cancer trial
Disease control CompletedThis phase 2 study tested three different drug combinations in 151 people with advanced non-small cell lung cancer that had not been treated before. The drugs help the immune system attack cancer cells. Researchers measured how many patients' tumors shrank or stopped growing, and…
Phase 2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer patients get continued access to promising targeted therapy
Disease control CompletedThis study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy before lung surgery shows promise in early trial
Disease control CompletedThis study tested giving immunotherapy drugs (nivolumab alone or with relatlimab) for four weeks before surgery in 90 people with early-stage non-small cell lung cancer. The goal was to see if this approach is feasible and helps shrink tumors before removal. Results help determin…
Phase 2 • Sponsor: University Hospital, Essen • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise against tough lung cancer in early trial
Disease control CompletedThis study tested an oral drug called PLB1001 in 145 people with advanced non-small cell lung cancer whose tumors have a specific genetic change (c-Met dysregulation). The main goal was to see how many patients' tumors shrank or disappeared. The drug is taken twice daily and aims…
Phase 2 • Sponsor: Beijing Pearl Biotechnology Limited Liability Company • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail aims to outperform current lung cancer therapy
Disease control CompletedThis study tested whether adding the experimental immunotherapy tiragolumab to a standard combination of atezolizumab and chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-squamous non-small cell lung canc…
Phase 2/3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Morning vs. afternoon chemo: which is better for lung cancer?
Disease control CompletedThis study looked at whether giving immunochemotherapy in the morning or afternoon affects how long people with advanced non-small cell lung cancer live without their disease getting worse. 210 patients were randomly assigned to receive treatment before or after 3 PM. The goal is…
Phase 3 • Sponsor: Hunan Province Tumor Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New immunotherapy cocktail takes on lung cancer in major trial
Disease control CompletedThis phase 3 trial tested whether combining two immunotherapy drugs, atezolizumab and tiragolumab, works better than the standard drug durvalumab for people with stage III lung cancer that cannot be surgically removed. The 829 participants had already received chemotherapy and ra…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Blood tests may help decide best time to switch lung cancer drugs
Disease control CompletedThis phase 2 trial tested two drugs, osimertinib and gefitinib, in 156 people with advanced EGFR-mutant lung cancer. The goal was to see if using blood tests (liquid biopsies) to detect genetic changes could help decide when to switch treatments, compared to standard scans. The s…
Phase 2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New lung cancer pill shows promise in Head-to-Head trial
Disease control CompletedThis phase 3 study tested alectinib against crizotinib in 303 people with advanced ALK-positive non-small cell lung cancer who had not received prior treatment. Participants took one of the two drugs twice daily until their cancer worsened or side effects became too severe. The m…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill combo shows promise against resistant lung cancer
Disease control CompletedThis study tested whether combining two targeted drugs, savolitinib and osimertinib, works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and has stopped responding to initial treatment.…
Phase 3 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to boost survival in advanced lung cancer
Disease control CompletedThis phase 3 trial tested whether adding plinabulin to the chemotherapy drug docetaxel helps people with advanced non-small cell lung cancer live longer. 559 participants who had already tried one or two prior treatments received either the combination or docetaxel alone. The stu…
Phase 3 • Sponsor: BeyondSpring Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase 1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase 1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail shows promise for Hard-to-Treat lung cancer
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy (carboplatin or cisplatin plus pemetrexed) and immunotherapy (atezolizumab, with or without bevacizumab) in 150 people with advanced non-squamous non-small cell lung cancer that has EGFR, ALK, or ROS1 mutations and has progr…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental drug targets Hard-to-Treat brain metastases
Disease control CompletedThis phase 2 trial tested a drug called patritumab deruxtecan (HER3-DXd) in 63 patients with breast cancer, lung cancer, or other solid tumors that had spread to the brain or the lining of the brain and spinal cord. The drug is designed to seek out and destroy cancer cells carryi…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Lung cancer treatment in hours, not weeks: new One-Day radiation trial shows promise
Disease control CompletedThis study tested a new way to deliver high-dose radiation to small lung tumors in just one day, instead of the usual two to three weeks. Ten patients with early-stage lung cancer or limited lung metastases received a single session of stereotactic body radiotherapy (SBRT) using …
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Lung cancer patients get new hope from Drug-Radiation combo
Disease control CompletedThis phase 2 trial tested a combination of FLT3 ligand immunotherapy (CDX-301) and stereotactic body radiotherapy (SBRT) in 33 adults with advanced non-small cell lung cancer that had worsened after standard treatments. The goal was to see if this approach could slow cancer growt…
Phase 2 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Gene-Tailored therapy shows promise for advanced lung cancer
Disease control CompletedThis study tested whether customizing chemotherapy based on specific gene mutations (EGFR and BRCA1) could improve outcomes for 153 patients with advanced lung adenocarcinoma. Participants received treatments matched to their tumor's genetic profile. The goal was to see if this p…
Sponsor: Spanish Lung Cancer Group • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Gene therapy cocktail shows promise for tough mesothelioma
Disease control CompletedThis phase 3 trial tested a new approach for malignant pleural mesothelioma, a rare and aggressive cancer of the lung lining. Researchers gave 53 patients a gene therapy (rAd-IFN) injected into the chest cavity, along with the drugs celecoxib and gemcitabine. The goal was to see …
Phase 3 • Sponsor: Ferring Ventures Limited • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New lung cancer pill outperforms standard treatment in major trial
Disease control CompletedThis study tested a new targeted therapy, AZD9291 (osimertinib), against the usual targeted drugs for people with a specific genetic mutation (EGFR) in advanced non-small cell lung cancer. Over 600 participants received either the new drug or standard care. The main goal was to s…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy shows promise in controlling advanced lung cancer
Disease control CompletedThis early-phase study tested whether combining the immunotherapy drug pembrolizumab with standard palliative radiation is safe for people with advanced lung cancer. Twenty-four participants received different doses of pembrolizumab alongside radiation, then continued pembrolizum…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy duo shows promise against tough cancers
Disease control CompletedThis study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not been treated or had stopped responding to prior therapy. The goal was to see if the combination could shrink t…
Phase 2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for lung cancer patients: experimental drug shrinks tumors after other treatments fail
Disease control CompletedThis study tested a new drug called AZD9291 in 603 people with advanced non-small cell lung cancer whose tumors had started growing again after previous targeted therapy. The main goals were to find the safest and most effective dose, measure how the drug moves through the body, …
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Lung cancer drug cocktail aims to extend life
Disease control CompletedThis Phase 3 trial tested whether adding custirsen to the chemotherapy drug docetaxel helps people with advanced non-small cell lung cancer live longer. The study involved 664 patients who had already tried one platinum-based treatment. Researchers compared survival between those…
Phase 3 • Sponsor: Achieve Life Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy aims to keep early lung cancer from returning
Disease control CompletedThis study tested whether giving the drug durvalumab after precise radiation therapy (SBRT) helps people with early-stage lung cancer stay cancer-free longer. About 106 patients with stage I non-small cell lung cancer who could not have surgery or chose not to were randomly assig…
Phase 2 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Pedometer program aims to cut hospital stays for cancer patients
Disease control CompletedThis study tested whether tracking daily steps with a simple pedometer could help identify cancer patients at high risk of being hospitalized during chemoradiotherapy. 40 adults with head and neck, lung, esophageal, or stomach cancer wore a pedometer and received extra support li…
Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo therapy shows promise for lung cancer patients without chemo
Disease control CompletedThis phase 2 trial tested a combination of the immunotherapy drug pembrolizumab and a personalized 4-week course of radiotherapy in 25 patients with advanced non-small cell lung cancer whose tumors had high PD-L1 levels. The goal was to see if this approach could control the canc…
Phase 2 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for advanced lung cancer: durvalumab shows promise in trial
Disease control CompletedThis study tested the drug durvalumab in 446 people with advanced non-small cell lung cancer who had already tried at least two prior treatments. The goal was to see if the drug could shrink tumors or slow the disease. Participants received infusions every two weeks for up to 12 …
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy shows promise in tough lung cancer battle
Disease control CompletedThis study tested whether adding a new drug called tiragolumab to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer without their cancer getting worse. About 490 adults who had not received prior treatment for this stage of canc…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control CompletedThis study tested a combination of an immune-boosting drug (durvalumab) and a precise, high-dose radiation treatment (SBRT) for people with stage III lung cancer that hadn't spread. The goal was to see if adding SBRT after standard chemoradiation could help control the cancer lon…
Phase 2 • Sponsor: Brown University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Targeted pill shows promise for rare lung cancer mutation in chinese patients
Disease control CompletedThis study tested an oral targeted drug called capmatinib in 36 Chinese adults with advanced non-small cell lung cancer that has a specific MET gene mutation (exon 14 skipping). The drug aims to block faulty signals that help cancer grow. Researchers measured how many patients' t…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for frail lung cancer patients: Chemo-Free combo shows promise
Disease control CompletedThis phase II trial tested a combination of thoracic radiotherapy and the immunotherapy drug durvalumab in 51 elderly or frail patients with stage III lung cancer who could not receive chemotherapy. The goal was to see if this approach is safe and can shrink tumors. The study foc…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Immunotherapy before lung cancer surgery shows promise in early trial
Disease control CompletedThis study tested the immunotherapy drug pembrolizumab in 35 people with early-stage non-small cell lung cancer. Participants received the drug before and after surgery to see if it could help the immune system attack cancer cells. The main goal was to check if surgery could stil…
Phase 2 • Sponsor: Neal Ready MD PhD • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Keytruda after lung surgery: can it keep cancer away?
Disease control CompletedThis phase 3 trial tested the drug pembrolizumab (Keytruda) against a placebo in 1,177 people with early-stage non-small cell lung cancer who had already had surgery. The goal was to see if pembrolizumab could delay the cancer from coming back. Participants received either the dr…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can cancer treatment also kick the habit? new study tests combined approach
Disease control CompletedThis study looked at whether adding a structured addiction treatment program to standard cancer care helps patients with head and neck or lung cancer quit smoking and reduce alcohol use. 133 patients were randomly assigned to either the integrated program or usual care. The main …
Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase 1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Real-World check: does zepzelca help advanced lung cancer patients?
Disease control CompletedThis study followed 272 adults with extensive-stage small cell lung cancer who were taking the drug Zepzelca. Researchers wanted to see how well the drug worked and how safe it was in real-world settings, not just in controlled trials. The goal was to measure tumor shrinkage, sur…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Maintenance chemo shows promise in slowing mesothelioma
Disease control CompletedThis study tested whether continuing chemotherapy with gemcitabine after initial treatment can help patients with diffuse pleural mesothelioma keep their cancer under control longer. 64 patients who responded to first-line chemo were randomly assigned to receive gemcitabine or no…
Phase 2 • Sponsor: National Cancer Institute, Egypt • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Light therapy shows promise in tough mesothelioma trial
Disease control CompletedThis pilot study tested whether adding intrapleural photodynamic therapy (PDT) to standard surgery and chemotherapy is safe and feasible for patients with malignant pleural mesothelioma. Six participants received a light-sensitive drug followed by laser light inside the chest cav…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Cancer drug bintrafusp alfa gets Long-Term safety check in small Follow-Up trial
Disease control CompletedThis study followed 22 cancer patients who were already taking bintrafusp alfa in earlier trials, to see how safe it is over the long term and how long they live. Participants continued receiving the drug until it was no longer helping or became available commercially. The main g…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo shows promise in advanced lung cancer trial
Disease control CompletedThis study tested whether adding a new drug called tiragolumab to the standard immunotherapy atezolizumab works better than atezolizumab alone for people with advanced non-small cell lung cancer that has not been treated before. About 620 participants with high levels of a protei…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Old malaria drug could boost lung cancer treatment
Disease control CompletedThis early-phase trial tested adding the anti-parasitic drug atovaquone to standard chemotherapy and radiation for people with locally advanced non-small cell lung cancer. The main goal was to find the safest dose of atovaquone in this combination. Twenty-one participants receive…
Phase 1 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase 1/2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo shows promise for lung cancer patients
Disease control CompletedThis study tested whether adding a new drug (LY2875358) to the standard treatment erlotinib helps people with advanced non-small cell lung cancer that has a specific gene mutation. All 168 participants first took erlotinib alone for 8 weeks. Those whose cancer did not worsen were…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Immunotherapy duo shows promise against rare lung cancer in chinese trial
Disease control CompletedThis study tested whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than standard chemotherapy for Chinese patients with advanced pleural mesothelioma, a rare cancer of the lung lining. 102 patients who could not have surgery were randomly a…
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Immunotherapy plus chemo shows promise in tough lung cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with advanced pleural mesothelioma live longer. The trial included 214 adults whose cancer could not be removed by surgery. Participants received either the combination or a s…
Phase 3 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Drug combo shows promise for tough cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…
Phase 1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Chemo-Immuno cocktail shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…
Phase 1/2 • Sponsor: Kristoffer Rohrberg • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New cancer drug MRX-2843 enters first human trial
Disease control CompletedThis early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…
Phase 1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New pill shows promise for lung cancer patients with Hard-to-Treat mutation
Disease control CompletedThis study tested a daily pill called AZD9291 in 171 people from Asia Pacific with advanced lung cancer that has a specific genetic change (T790M mutation). The goal was to see if the drug could shrink tumors and control the disease after other treatments stopped working. Researc…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug ZGGS15 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…
Phase 1 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Immunotherapy combo shows promise in early lung cancer trial
Disease control CompletedThis phase 3 trial tested whether adding the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) to standard chemotherapy could improve outcomes for people with early-stage non-small cell lung cancer that can be surgically removed. The study enrolled 505 participants a…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Tailored radiation boosts lung cancer control in new trial
Disease control CompletedThis study tested whether giving personalized radiation doses based on PET scans during treatment could improve local control in patients with inoperable stage III non-small cell lung cancer. 158 participants received either standard radiation or a higher, tailored dose to areas …
Phase 2 • Sponsor: Centre Henri Becquerel • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill shows promise in early trial for tough cancers
Disease control CompletedThis early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …
Phase 1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New combo aims to outsmart tough lung cancer
Disease control CompletedThis study tested whether combining the immunotherapy atezolizumab (Tecentriq) with the targeted drug cabozantinib works better than the standard chemotherapy docetaxel for people with advanced non-small cell lung cancer that has worsened after prior treatment. The trial enrolled…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for mesothelioma patients: experimental drug tested in 47-person trial
Disease control CompletedThis phase II trial tested a drug called Bintrafusp alfa (M7824) in 47 people with advanced pleural mesothelioma that had worsened after platinum-based chemotherapy. The drug aims to block two proteins that help tumors grow. Researchers measured how long patients lived without th…
Phase 2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New pill could outperform chemo for rare lung cancer mutation
Disease control CompletedThis Phase 3 trial tested a targeted cancer pill called pyrotinib against standard chemotherapy (docetaxel) in 151 people with advanced non-squamous non-small cell lung cancer that has a specific HER2 mutation. All participants had already tried platinum-based chemo without succe…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Immunotherapy combo shows promise in advanced lung cancer trial
Disease control CompletedThis phase 3 trial tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 719 patients who had not received prior treatment took part. The study compared the combin…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Your own tumor cells could be the key to fighting cancer
Disease control CompletedThis early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…
Phase 1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New immunotherapy cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Radiation before Chemo-Immunotherapy shows promise in advanced lung cancer
Disease control CompletedThis study looked at whether giving palliative radiation to several tumor sites before starting standard immunotherapy and chemotherapy can help people with metastatic non-small cell lung cancer. Fifty adults with cancer that had spread and low PD-L1 levels received radiation to …
Phase 2 • Sponsor: University Medical Centre Maribor • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a week of breathing support before lung surgery cut risks in half?
Disease control CompletedThis study tested whether using a non-invasive ventilation machine for at least 7 days before lung cancer surgery could reduce lung and heart complications. The trial included 300 patients with lung cancer who also had breathing problems, obesity, or heart failure. The goal was t…
Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug combo shows promise for tough lung cancer
Disease control CompletedThis study tested a combination of two drugs, atezolizumab and bevacizumab, as the first treatment for people with advanced non-squamous lung cancer that has a high number of genetic mutations. The goal was to see if this drug pair could slow down cancer growth. The trial enrolle…
Phase 2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Neck surgery before Chemo-Radiation may reduce side effects in head and neck cancer patients
Disease control CompletedThis study looked at 65 people with advanced head and neck cancer that had spread to lymph nodes. It compared two approaches: having surgery to remove affected lymph nodes before chemo-radiation, versus chemo-radiation alone. The goal was to see if upfront surgery could reduce tr…
Phase 3 • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug shrinks tumors in some Hard-to-Treat lung cancers
Disease control CompletedThis study tested a drug called trastuzumab deruxtecan in 152 people with advanced non-small cell lung cancer that has a specific genetic change (HER2 mutation) and has stopped responding to standard chemotherapy. The drug is given by IV every three weeks and aims to shrink tumor…
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug combo aims to overcome resistance in lung cancer treatment
Disease control CompletedThis early-phase trial tested whether adding copanlisib to the standard immune therapy durvalumab is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 11 participants who had already received chemotherapy and radiation…
Phase 1 • Sponsor: Zhonglin Hao • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can lung cancer patients safely stop immunotherapy after 6 months?
Disease control CompletedThis phase 3 trial tested whether patients with advanced non-small cell lung cancer (NSCLC) who received initial immunotherapy (nivolumab and ipilimumab) for 6 months could safely stop treatment and be monitored, instead of continuing therapy indefinitely. The study enrolled 265 …
Phase 3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control CompletedThis study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase 1/2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Immunotherapy cocktail shows promise in advanced lung cancer battle
Disease control CompletedThis study tested whether combining the immunotherapy drug nivolumab with another drug (ipilimumab) or with standard chemotherapy could help people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 2,700 patients who had not received pr…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…
Phase 1/2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Real-World tagrisso study shows promise for lung cancer patients
Disease control CompletedThis study looked at how well the drug Tagrisso (osimertinib) works and how safe it is for people with a certain type of lung cancer (non-small cell lung cancer with EGFR mutations) in everyday medical practice. Over 900 patients in Korea were observed while taking Tagrisso as th…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Triple-Drug cocktail shows promise for untreated lung cancer
Disease control CompletedThis phase II trial tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy (paclitaxel) in 46 people with untreated metastatic non-small cell lung cancer. The goal was to see if the mix could slow cancer growth and be safe. Results may point …
Phase 2 • Sponsor: Jeffrey Clarke • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for frail lung cancer patients: immunotherapy drug tested
Disease control CompletedThis study tested the immunotherapy drug durvalumab in 50 patients with advanced lung cancer who were too weak for standard chemotherapy. The goal was to see if the drug is safe and helps control the disease. Researchers focused on side effects and how well patients responded.
Phase 2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New combo therapy aims to stop head and neck cancer return
Disease control CompletedThis phase II trial tested whether adding the targeted drug cetuximab to standard chemotherapy and radiation could help prevent head and neck cancer from coming back after surgery. The study enrolled 53 patients with certain high-risk features. The main goal was to see how many p…
Phase 2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could a bone marrow shield make chemotherapy safer for lung cancer patients?
Disease control CompletedThis study tested a drug called trilaciclib in 123 people with advanced small cell lung cancer who were getting chemotherapy. The goal was to see if trilaciclib could protect the bone marrow and immune system from chemotherapy damage, reducing severe side effects like low white b…
Phase 1/2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New pill shows promise against lung cancer brain metastases
Disease control CompletedThis study tested a new drug called AZD3759 against standard targeted therapies (erlotinib or gefitinib) in 492 people with advanced EGFR-mutant lung cancer that had spread to the brain. The goal was to see if AZD3759, which is designed to better reach the brain, could keep the c…
Phase 2/3 • Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:13 UTC
-
Lung cancer showdown: which targeted pill works better after crizotinib fails?
Disease control CompletedThis phase 3 trial tested two targeted drugs, brigatinib and alectinib, in 248 people with advanced ALK-positive non-small-cell lung cancer whose cancer had worsened after taking crizotinib. Participants were randomly assigned to take either brigatinib or alectinib daily. The mai…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 26, 2026 16:05 UTC
-
Lung cancer drug combo fails to extend survival in major trial
Disease control CompletedThis large Phase 3 trial tested whether adding aflibercept (a drug that blocks blood vessel growth) to standard chemotherapy (docetaxel) could help people with advanced non-small cell lung cancer live longer. Over 900 participants who had already tried one platinum-based treatmen…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
Hope for frail lung cancer patients: immunotherapy combo shows promise
Disease control CompletedThis study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with advanced small cell lung cancer who are in poor health. The trial included 70 patients with extensive-stage disease and a low performance status (ECOG 2). Researcher…
Phase 2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jun 26, 2026 15:06 UTC
-
New cocktail aims to stall lung cancer progression
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug lenvatinib to standard chemotherapy plus the immunotherapy pembrolizumab helps people with advanced nonsquamous non-small cell lung cancer live longer without their cancer growing. The study enrolled 201 adults in China w…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 26, 2026 14:55 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Phase 1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
A single blood draw to detect five cancers before symptoms appear?
Diagnosis CompletedThis trial tests a blood-based test designed to detect multiple cancers early in people aged 40 to 74 who have no cancer symptoms. The study will enroll about 2,500 participants and will check how well the test identifies lung, colorectal, liver, gastric, and esophageal cancers. …
Sponsor: Shanghai Weihe Medical Laboratory Co., Ltd. • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
New PET scan trick may spot fake tumor growth in immunotherapy patients
Diagnosis CompletedThis study looked at whether a special PET scan (18FDG dual-point) can tell the difference between real tumor growth and harmless inflammation caused by immunotherapy. Researchers studied 100 people with advanced lung cancer or melanoma who were being treated with drugs like nivo…
Sponsor: Centre Antoine Lacassagne • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
Diagnosis CompletedThis early-phase trial tests whether a PET/CT scan using an investigational tracer called zirconium Zr 89 crefmirlimab berdoxam can safely and effectively spot CD8+ T cells—key immune cells that attack cancer—in people with metastatic non-small cell lung cancer. Participants are …
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Aug 28, 2026 00:00 UTC
-
Can a scanner instantly tell if a lung biopsy is good enough?
Diagnosis CompletedThis study tests a new scanner that uses light-based imaging to quickly check whether small lung tissue samples taken during a bronchoscopy are adequate for diagnosis. The goal is to see if the scanner can accurately tell apart samples that are usable from those that aren't, comp…
Sponsor: Aquyre Bioscience, Inc • Aim: Diagnosis
Last updated Aug 20, 2026 00:00 UTC
-
Could a bronchial wash detect lung cancer mutations faster?
Diagnosis CompletedThis study investigates whether a liquid biopsy taken from the airways during a bronchoscopy can help diagnose lung cancer and identify genetic mutations. The approach aims to be less invasive and faster than traditional tissue biopsies. Researchers will compare the accuracy of t…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Breath test could revolutionize lung cancer detection
Diagnosis CompletedThis study is testing a new breath test called OWL-EVO1 to see if it can accurately tell the difference between people who have lung cancer and those who do not. The test involves breathing into a device after taking a special probe. Researchers are enrolling adults aged 45-85 wh…
Phase 2 • Sponsor: Owlstone Ltd • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
AI-Powered CT scan cuts radiation while spotting lung nodules
Diagnosis CompletedThis study tested whether an ultra-low dose CT scan, combined with a deep-learning AI reconstruction, can detect lung nodules as accurately as the standard low-dose CT. 70 adults having a chest CT for nodule check-up or follow-up received an extra ultra-low dose scan. The goal wa…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Simple spit test could spot cancer before symptoms appear
Diagnosis CompletedThis study aimed to create easy, non-invasive tests using blood and saliva to find markers of certain cancers, like breast and lung cancer. Researchers worked with 250 adults who had these cancers but hadn't started treatment yet. The goal was to improve early detection and monit…
Sponsor: ASL Lecce • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
New laser tool may help doctors pinpoint lung nodules during biopsy
Diagnosis CompletedThis study tested a new imaging tool called needle-based confocal laser endomicroscopy (nCLE) to help doctors locate lung nodules during robotic-assisted bronchoscopy. 53 adults with lung nodules at risk for cancer took part. The goal was to see if the tool could safely and accur…
Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
Glow-in-the-Dark dye helps surgeons spot hidden lung cancer
Diagnosis CompletedThis study tested a special fluorescent dye called VGT-309 that makes lung cancer cells glow during surgery. About 89 people with known or suspected lung cancer received the dye before their operation. The goal was to see if the dye helps surgeons find tumors that are hard to see…
Phase 2 • Sponsor: Vergent Bioscience, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Electric probe could help doctors spot lung cancer in real time
Diagnosis CompletedThis study tested a new smart probe that uses electrical signals to tell the difference between healthy lung tissue and tumors during a biopsy. 30 adults with lung lesions took part. The goal was to see if the probe could help doctors make more accurate diagnoses during the proce…
Sponsor: Sensome • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Can a simple CT scan catch lung cancer early in HIV smokers?
Diagnosis CompletedThis pilot study tested whether low-dose CT scans can help find lung cancer early in HIV-positive people who are heavy smokers. Researchers scanned 450 participants to see how many had lung cancer and what types were found. The goal was to learn if this screening method is useful…
Sponsor: ANRS, Emerging Infectious Diseases • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New lung camera could spot cancer in real time
Diagnosis CompletedThis study tested a special microscope on a thin probe (confocal endo-microscopy) that doctors can use during a bronchoscopy to look at lung nodules up close. The goal was to see if it can help tell whether a nodule is cancer or not, right then and there. 120 adults with a lung n…
Sponsor: University Hospital, Rouen • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
Can a special PET scan outperform MRI for spotting brain tumors?
Diagnosis CompletedThis study tested whether a special PET scan (called 18F-DOPA PET-CT) can find brain metastases as well as or better than standard MRI in people with lung cancer, breast cancer, or melanoma. 32 adults with untreated brain metastases took part. The goal was to see if this PET meth…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Online tool aims to catch lung cancer earlier
Diagnosis CompletedThis completed study tested a tool called MyLungHealth, delivered through a patient portal, to help more people get screened for lung cancer. Over 31,000 participants aged 50-79 with a smoking history were involved. The tool aimed to identify who was eligible for screening and en…
Sponsor: University of Utah • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
Blood test may replace painful lung biopsies for some cancer patients
Diagnosis CompletedThis study tested whether a blood test can detect ALK gene rearrangements in lung cancer patients, which currently requires an invasive tumor biopsy. Researchers analyzed circulating tumor cells from blood samples of 206 patients with advanced lung cancer. The goal was to see if …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
Can a simple blood test catch lung cancer earlier in smokers with COPD?
Diagnosis CompletedThis study looked at whether a blood test for circulating tumor cells (CTCs) can help detect lung cancer earlier in people at very high risk: smokers and ex-smokers with COPD. Researchers combined this blood test with low-dose CT scans over three yearly screenings in 683 particip…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
Can a simple blood test replace tissue biopsies for lung cancer?
Diagnosis CompletedThis study looked at whether a blood test can find gene changes in people with advanced lung cancer. 22 adults gave a blood sample, and the results were compared to standard tissue tests. The goal was to see if the blood test is a reliable and practical option for guiding treatme…
Sponsor: Institute of Oncology Ljubljana • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
Blood test may spot lung cancer mutations faster
Diagnosis CompletedThis study looked at whether a simple blood test (liquid biopsy) can detect EGFR gene mutations in people with advanced non-small cell lung cancer. Researchers collected blood samples from 581 patients and compared the results with standard tissue testing. The goal was to see if …
Sponsor: Institut Bergonié • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
Double scan boosts detection of hidden cancer in neck nodes
Diagnosis CompletedThis study tested a new way to find small cancer spots in neck lymph nodes of people with nasopharyngeal cancer. Researchers combined MRI scans with a special ultrasound that uses a contrast agent. They aimed to create a better rule for spotting these tiny metastases. 348 patient…
Sponsor: Sun Yat-sen University • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
Blood test may cut cancer diagnosis time
Diagnosis CompletedThis study looked at whether using a liquid biopsy (a blood test that detects cancer DNA) early in the diagnostic process could help doctors diagnose and recommend treatment faster for people with advanced lung or gastrointestinal cancer. 463 participants were enrolled across mul…
Sponsor: Hoffmann-La Roche • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
Blood test aims to catch lung cancer earlier in smokers
Diagnosis CompletedThis study tested whether giving doctors access to a blood test called FirstLook increases lung cancer screening rates among people at high risk. The test looks for DNA fragments in the blood that may signal lung cancer. Researchers compared screening rates in practices that coul…
Sponsor: Delfi Diagnostics Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
New breathing technique could sharpen lung cancer scans
Diagnosis CompletedThis study tested a special breathing technique during PET scans to get clearer images of lung tumors. 103 people with small lung nodules (under 35 mm) had both a standard PET scan and an extra scan where they held their breath. The goal was to see if this reduces blurring from b…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 26, 2026 19:11 UTC
-
Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
Prevention CompletedResearchers are testing whether pirfenidone, a drug that reduces inflammation and scarring, can prevent radiation pneumonitis in people with advanced lung cancer. Participants have already received immune checkpoint inhibitors and need chest radiation. The trial gives pirfenidone…
Phase 2 • Sponsor: Hubei Cancer Hospital • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Can an Immune-Boosting drug stop lung cancer from returning?
Prevention CompletedThis phase III trial tests whether the immunotherapy drug durvalumab (MEDI4736) can prevent non-small cell lung cancer from returning after patients have surgery and possibly chemotherapy. Participants have completely resected stage IB, II, or IIIA lung cancer and are randomly as…
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Fellow veterans may hold the key to earlier lung cancer detection
Prevention CompletedThis pilot study tests a peer-led program designed to help Black Veterans at high risk for lung cancer get screened. Veterans who have not yet had lung cancer screening will receive group orientations and one-on-one support from a peer to navigate the process. The study aims to s…
Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase 2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Infrared tech could take the pain out of IVs for lung cancer patients
Symptom relief CompletedThis study tests whether a special infrared light can help nurses see veins better when placing IVs in lung cancer patients receiving chemotherapy. The goal is to reduce pain, improve comfort, and strengthen trust between patients and nurses. About 160 patients will take part, wi…
Sponsor: Ataturk University • Aim: Symptom relief
Last updated Sep 21, 2026 17:00 UTC
-
Smaller chest drain may speed recovery after lung cancer surgery
Symptom relief CompletedResearchers compare two chest drain sizes, 20-Fr and 24-Fr, in people having part of a lung removed for early-stage lung cancer. After surgery, each participant receives one of the two drains to clear fluid and air from the chest. The trial tracks complications such as collapsed …
Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Virtual reality vs. relaxing videos: a new weapon against chemo side effects?
Symptom relief CompletedThis trial tests whether immersive virtual reality or relaxing nature videos can reduce symptom severity, distress, and improve quality of life in people with lung cancer who are starting chemotherapy. Participants will be randomly assigned to one of three groups: virtual reality…
Sponsor: Hacettepe University • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can a structured exercise plan speed recovery after lung cancer surgery?
Symptom relief CompletedResearchers test a guided exercise program for people aged 60 and older recovering from lung cancer surgery. The program combines breathing exercises, shoulder training, and strength work, taught through videos and a manual. The trial measures how far participants can walk in six…
Sponsor: Sir Run Run Shaw Hospital • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Exercise and diet combo tested for head and neck cancer recovery
Symptom relief CompletedThis study tests whether a program combining resistance training and a Mediterranean diet is practical and helpful for people with head and neck cancer undergoing radiation. Forty participants will receive supervised exercise sessions and pre-made meals, plus dietary coaching. Th…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Which nerve block wins for lung surgery pain?
Symptom relief CompletedResearchers compare two ultrasound-guided nerve blocks to see which one better controls pain after video-assisted thoracoscopic surgery (VATS), a minimally invasive lung operation. The trial enrolls 46 adults scheduled for VATS. Participants receive either a serratus posterior su…
Sponsor: Medipol University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Get up and eat! new study says early activity after lung surgery speeds recovery
Symptom relief CompletedThis study tested a new care plan that gets people eating and moving sooner after lung surgery. 232 adults took part. The goal was to see if this approach, based on the ERAS protocol, improves recovery quality, reduces complications, and shortens hospital stays compared to standa…
Sponsor: Jianxing He • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
One operation, two lungs: talc procedure tested for fluid around both lungs
Symptom relief CompletedResearchers are studying whether they can safely perform talc pleurodesis on both lungs at the same time in people with malignant pleural effusions, which is fluid that builds up around the lungs because of cancer. The procedure uses medical-grade talc to seal the space around th…
Sponsor: European Institute of Oncology • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can teaching patients about immunotherapy cut severe side effects?
Symptom relief CompletedThis trial tests whether a structured patient education program can lower the risk of severe immune-related side effects in people receiving immunotherapy for certain cancers, including melanoma, lung, kidney, and head and neck cancers. Participants either attend five educational…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Can an AI chatbot lift the spirits of advanced cancer patients?
Symptom relief CompletedThis trial tests whether an AI emotional companion app can improve depression, anxiety, and demoralization in adults with advanced cancer. Participants use a mobile app where a virtual character holds conversations, reads emotional cues, and offers a link to a human hotline if di…
Sponsor: National Yang Ming Chiao Tung University • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
A card game could open the door to better End-of-Life conversations
Symptom relief CompletedThis study tests whether a conversation game called 'Hello' can help people with cancer and their loved ones discuss advance care planning—decisions about future medical care. Participants will play either the Hello game or a similar conversation game, complete questionnaires, an…
Sponsor: Milton S. Hershey Medical Center • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
Can light therapy unblock a common cancer side effect?
Symptom relief CompletedThis trial tests whether laser acupuncture, a non-invasive therapy using low-intensity light on traditional acupoints, can relieve constipation in people with advanced cancer. Participants are adults with advanced cancer who have constipation despite using laxatives. The study me…
Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
A good Night's sleep for cancer patients? video therapy put to the test
Symptom relief CompletedThis pilot study explores whether cancer patients are willing to complete a quick self-screening for insomnia during clinic visits, and whether a video-based cognitive behavioral therapy (CBT-I) could help them sleep better. The study involves adults with breast, colorectal, lung…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Peppermint and lemon scents put to the test against chemo nausea
Symptom relief CompletedThis phase 2 trial tests whether inhaling a blend of peppermint and lemon essential oils can reduce nausea and vomiting in people receiving their first chemotherapy for a solid tumor. Participants will inhale the oils four times daily and whenever nausea strikes, with symptoms tr…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
Symptom relief CompletedThis trial tests whether a mouthwash containing lithium can prevent or reduce oral mucositis (painful mouth sores) and dysgeusia (taste changes) in people receiving radiation for head and neck tumors. Participants will rinse with either a lithium mouthwash or a placebo during the…
Phase 1/2 • Sponsor: West China Hospital • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Herbal extract may ease the toll of lung cancer immunotherapy
Symptom relief CompletedThis pilot study tests whether a daily herbal supplement made from Lindera obtusiloba can improve quality of life for people with non-small cell lung cancer who are receiving PD-1 or PD-L1 inhibitor immunotherapy. About 20 adults will take the supplement for 8 weeks alongside the…
Sponsor: Jun-Yong Choi • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
Symptom relief CompletedThis trial tests whether a new care approach, called PediQUEST Response, can improve quality of life for children, adolescents, and young adults with advanced cancer. Participants use an app to regularly report symptoms and quality of life, and a palliative care team receives the…
Sponsor: Joanne Wolfe, MD, MPH • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Family support may be key to easing lung cancer surgery stress
Symptom relief CompletedThis study tests whether teaching family caregivers about lung cancer care—through a handbook and personalized guidance—can reduce stress and improve quality of life for patients undergoing lung cancer surgery. The trial involves 160 patients and their caregivers, with some recei…
Sponsor: Anhui Medical University • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Facing the fear: a new program aims to ease anxiety in advanced cancer
Symptom relief CompletedThis study tests a psychosocial program called Conquer Fear Support (CFS) for people with stage III or IV lung or gynecologic cancer who are experiencing fear of cancer progression. The program includes psychoeducation, attention training, worry management, and detached mindfulne…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Virtual reality goggles could ease cancer Patients' procedure fears
Symptom relief CompletedThis study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Could a nebulized cocktail make lung scopes less Cough-Inducing?
Symptom relief CompletedThis trial tests whether adding nebulized ketamine to lidocaine before a fiberoptic bronchoscopy reduces coughing and discomfort compared to lidocaine alone or standard spray. About 134 adults scheduled for bronchoscopy will receive one of three premedication approaches. The stud…
Phase 4 • Sponsor: Alexandria University • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Which palliative care approach boosts quality of life in advanced lung cancer?
Symptom relief CompletedThis study looks at two ways of delivering palliative care—specialized support to ease symptoms and stress—for people recently diagnosed with advanced lung cancer. One approach starts with basic palliative care and adds more if needed, while the other provides full palliative car…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Can talking it out ease PTSD in cancer patients during a pandemic?
Symptom relief CompletedThis study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see…
Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Ancient Mind-Body practice tested as fatigue fighter for men after cancer
Symptom relief CompletedThis study investigates whether a 12-week program of tai chi and qigong (called Body Mind Training) can reduce fatigue in male cancer survivors aged 55 and older. Participants are randomly assigned to the mind-body training, a light exercise-only group, or a usual-care group. Res…
Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Can bright light help lung cancer patients sleep better and age slower?
Symptom relief CompletedThis trial tests whether daily bright light therapy can improve sleep and reduce biological aging in people with lung cancer. Participants wear a light visor for 4 weeks and track sleep, fatigue, and stress. The study compares bright light to usual light exposure to see if it hel…
Sponsor: Henry Ford Health System • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Could a structured nursing program boost quality of life in advanced lung cancer?
Symptom relief CompletedThis trial investigates whether an 8-week systematic symptom management nursing program can improve quality of life, self-management skills, and psychological resilience in people with advanced (stage IIIB–IV) lung cancer. Participants are randomly assigned to receive either rout…
Sponsor: Jie Zeng • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Breathing trick could sharpen lung cancer radiation
Symptom relief CompletedThis pilot study tests a breathing method called percussive ventilation breathhold (PVB) to help people hold still during lung cancer radiation. The goal is to see if the technique can be used successfully by healthy volunteers and lung cancer patients. If it works, it may allow …
Sponsor: Stanford University • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Beauty treatments ease cancer pain and anxiety, study finds
Symptom relief CompletedThis study tested whether professional socio-aesthetics (specialized beauty and well-being care) can improve quality of life, reduce pain, and ease anxiety in adults undergoing chemotherapy for lung, breast, colon, or prostate cancer. 400 participants were randomly assigned to re…
Sponsor: Centre Hospitalier de Valence • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Spray before biopsy may curb bleeding and boost cancer diagnosis
Symptom relief CompletedThis study tested whether spraying a drug called terlipressin into the airways before taking biopsy samples can reduce bleeding. The goal was to allow doctors to safely take more tissue samples, which could improve the chances of diagnosing lung cancer. The trial involved 130 adu…
Phase 3 • Sponsor: University Hospital, Rouen • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Walking your way to recovery: exercise program boosts lung cancer surgery outcomes
Symptom relief CompletedThis study tested whether a personalized exercise program helps people with early-stage lung cancer or cancer that spread to the lungs recover better after surgery. 182 participants were randomly assigned to either the exercise program or usual care. The main goal was to see if t…
Phase 3 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New drug targets wasting syndrome in cancer patients
Symptom relief CompletedThis study tested an investigational drug called ponsegromab in 187 adults with lung, pancreatic, or colorectal cancer who also had cachexia—a condition causing severe weight loss, loss of appetite, and fatigue. The goal was to see if ponsegromab could help patients gain weight a…
Phase 2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Can a drug stop the agony of mouth sores during cancer therapy?
Symptom relief CompletedThis phase 3 trial tested whether ulinastatin, a drug that blocks certain enzymes, can reduce severe mouth sores caused by chemoradiotherapy in 179 patients with advanced nasopharyngeal cancer. Patients received either standard care or ulinastatin alongside their cancer treatment…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Shorter radiation course may ease treatment burden for lung cancer patients
Symptom relief CompletedThis study tested two different radiotherapy schedules for people with advanced non-small cell lung cancer. One group received the standard 6-week course, while the other had a shorter 4-week course guided by PET scans. The main goal was to see how patients felt during and after …
Phase 2 • Sponsor: Albert Einstein College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Lung cancer patients breathe easier with simple rehab program
Symptom relief CompletedThis study tested an 8-week supervised program of breathing exercises and light strength training for 30 people with advanced lung cancer (stage IIIB/IV) who were also getting chemotherapy. Those in the rehab group could walk farther, breathe better, and reported less coughing an…
Sponsor: Istanbul Medipol University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Can Self-Kindness ease lung cancer stigma? new study says maybe
Symptom relief CompletedThis pilot study tested a 10-week virtual group program called Mindful Self-Compassion for Lung Cancer (MSC-LC) in 79 adults with lung cancer who felt stigmatized. Participants were randomly assigned to the program or a waitlist that received mental health resources. The goal was…
Sponsor: Loyola Marymount University • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Team nursing approach shows promise for lung cancer patients on immunotherapy
Symptom relief CompletedThis study tested a team-based nursing program for 200 people with advanced small cell lung cancer receiving chemotherapy plus immunotherapy. The program included close monitoring for side effects, help with medication adherence, nutrition and exercise support, and psychological …
Sponsor: Shanxi Province Cancer Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Gentle gymnastics and nursing care ease fatigue in lung cancer patients
Symptom relief CompletedThis study looked at whether adding a structured, gentle exercise program to standard nursing care could help reduce cancer-related fatigue and improve quality of life in people with advanced lung cancer receiving chemotherapy. One hundred patients were split into two groups: one…
Sponsor: Shanxi Province Cancer Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Can family support ease the burden of advanced lung cancer?
Symptom relief CompletedThis study tested whether a family-supported palliative care program could improve quality of life and emotional well-being in 110 people with advanced lung cancer. Participants were randomly assigned to either the family-supported program or standard nursing care for 8 weeks. Th…
Sponsor: Shanxi Province Cancer Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Smart radiotherapy aims to spare saliva glands in head and neck cancer patients
Symptom relief CompletedThis study tested a new type of radiation therapy that adjusts the treatment beam each day based on the patient's current anatomy. The goal was to see if this daily adaptive approach could reduce chronic dry mouth (xerostomia) compared to standard radiation in 50 people with head…
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Home workouts before lung surgery may cut hospital stays
Symptom relief CompletedThis study tested whether a 3-week home exercise program before lung cancer surgery could help patients recover more quickly. 90 patients with lung cancer and COPD were split into two groups: one received only chest physiotherapy, the other added home exercise training. Researche…
Sponsor: Centre Jean Perrin • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Acupuncture offers hope for cancer survivors suffering from chronic dry mouth
Symptom relief CompletedThis study looked at whether acupuncture can reduce dry mouth (xerostomia) caused by radiation therapy in people with head and neck cancer. A total of 258 participants were randomly assigned to receive acupuncture or usual care. The main goal was to see if acupuncture improved dr…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
App aims to boost cancer patients' well-being at home
Symptom relief CompletedThis completed trial tested a web-based remote monitoring platform called CONTINUUM+ CONNECT in 411 adults with metastatic breast, lung, colorectal, or prostate cancer. Patients used the platform to report symptoms and receive alerts, aiming to improve their physical health and q…
Sponsor: Centre Paul Strauss • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Talking through cancer: can couples therapy ease the emotional toll?
Symptom relief CompletedThis study tested a program that teaches couples communication skills when one partner has advanced cancer. About 440 patients and their partners took part, with half receiving the training and half getting general healthy living information. The goal was to see if the training c…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New breathing tube may spare your throat during lung surgery
Symptom relief CompletedThis study tested whether using a laryngeal mask with a special bronchial blocker causes less sore throat and hoarseness after lung surgery compared to the standard double-lumen tube. 270 adults having lung surgery took part. The goal was to see which device leads to fewer throat…
Sponsor: Tingting Li • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Foot massage may ease chemo sickness in cancer patients
Symptom relief CompletedThis study looked at whether foot reflexology—a type of foot massage—can reduce nausea and vomiting caused by platinum-based chemotherapy. Eighty people with lung or digestive cancer received reflexology sessions during their chemo infusions and were asked to do self-massage betw…
Sponsor: Hospices Civils de Lyon • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
App-Based rehab after cancer surgery shows promise in small study
Symptom relief CompletedThis study tested a digital platform designed to help patients recover physically and mentally after major surgery for esophageal or laryngeal cancer. The platform offered short daily exercise sessions. The study included 30 patients and focused on whether they would use the tool…
Sponsor: University Hospital, Lille • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Emotional skills boost for cancer survivors: new study shows promise
Symptom relief CompletedThis study tested whether teaching emotional skills (like identifying and managing feelings) can help people who finished cancer treatment. 26 patients with digestive or lung cancer took part. Some received emotional skills training, others did relaxation exercises. The goal was …
Sponsor: University Hospital, Lille • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
VR movies calm cancer patients before radiation
Symptom relief CompletedThis study tested whether watching 360° virtual reality movies can reduce fear and anxiety in cancer patients about to start radiation therapy. 292 adults with breast, lung, prostate, head and neck cancer, or brain tumors participated. Patients watched a VR movie and then filled …
Sponsor: Maastricht Radiation Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
New online program eases Kids' cancer return to school
Symptom relief CompletedThis study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…
Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Why do Non-Smokers get head and neck cancer? scientists probe tumor DNA
Knowledge-focused CompletedResearchers are studying blood and tumor tissue from people with squamous cell cancer of the larynx, pharynx, or oral cavity who have no history of smoking, heavy drinking, or workplace exposure to substances like asbestos or wood dust. The goal is to learn how DNA changes and bi…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can a care checklist speed up recovery from lung cancer surgery?
Knowledge-focused CompletedThis study looks at whether closely following a standard enhanced recovery after surgery (ERAS) protocol affects nutritional status in 120 adults undergoing lung cancer surgery. Researchers will measure nutritional risk and a nutritional index before surgery and two days after, a…
Sponsor: Bursa City Hospital • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Should all young cancer patients get genetic testing? study investigates
Knowledge-focused CompletedThis study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists create massive biobank to uncover lung Cancer's earliest clues
Knowledge-focused CompletedThis study collected and stored biological samples from nearly 10,000 tin miners in China who are at high risk for lung cancer due to workplace exposures. The goal is to use these samples to discover early markers of the disease, which could lead to better screening and preventio…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Mining Responders' tumors for clues to a universal cancer therapy
Knowledge-focused CompletedResearchers want to learn which molecules on cancer cells the immune system attacks when checkpoint inhibitor drugs work well. They collect tumor and blood samples from adults with solid tumors who respond to these drugs, either during treatment or after surgery. The team then se…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Glow-in-the-dark dye may help surgeons spot hidden cancer in kids
Knowledge-focused CompletedThis study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
AI steps into the lab: could computers speed up cancer diagnosis?
Knowledge-focused CompletedThis study looks at how doctors currently diagnose lung and breast cancer using tissue samples. It will also test whether artificial intelligence (AI) can help analyze these samples faster and more accurately. Researchers will review records from 600 patients to measure diagnosis…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Scientists probe how lung cancer outsmarts key drugs
Knowledge-focused CompletedThis study looks at why lung cancer cells stop responding to a class of drugs called EGFR inhibitors. Researchers will collect blood samples from 80 patients over time to track changes in tumor DNA and cells. The goal is to understand the early steps of drug resistance and find w…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Sharper scans may make cancer radiation more precise
Knowledge-focused CompletedThis study tested a new cone-beam CT scanner that takes clearer pictures during radiation therapy for lung, liver, and breast cancers. 31 people participated to see if the new scanner reduces image blurring and improves accuracy. The goal is to help doctors target tumors more pre…
Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
A new tool aims to demystify immunotherapy for advanced cancer patients
Knowledge-focused CompletedThis trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
A 5-minute quiz might predict who gets severe chemo side effects
Knowledge-focused CompletedThis study looks at whether a short risk-assessment tool, called the CARG score, can predict severe side effects from chemotherapy in cancer patients aged 70 and older. Participants will answer questions about their health and daily function before starting a new chemotherapy reg…
Sponsor: RenJi Hospital • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
A sharper eye on lung cancer: could PET scans and blood tests outsmart relapse?
Knowledge-focused CompletedThis trial is testing whether using whole-body PET/CT scans and liquid biopsies (blood tests that detect cancer DNA) can improve the follow-up care of people who have completed treatment for early-stage non-small cell lung cancer. The goal is to see if these advanced tools can fi…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Blood test may spare cancer patients unneeded iron infusions
Knowledge-focused CompletedThis trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Massive Real-World study tracks Atezolizumab's performance in routine cancer care
Knowledge-focused CompletedThis study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Could your lifestyle or genes cause lung cancer before 50? new study investigates.
Knowledge-focused CompletedThis 100% remote study surveys 250 people diagnosed with non-small cell lung cancer before age 50. Participants answer questions about their environment, lifestyle, and family history, and may donate blood. The goal is to uncover factors linked to genetic changes that drive young…
Sponsor: Addario Lung Cancer Medical Institute • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can a CT-Free navigation system pinpoint lung nodules with precision?
Knowledge-focused CompletedThis study is testing whether a CT-free electromagnetic navigation system can accurately locate small lung nodules before surgery, compared to the standard CT-guided method. The goal is to see if the new approach can mark nodules within 10 millimeters of their center, which is cr…
Sponsor: Jianle Chen • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can tumor genetics predict survival in nasopharyngeal cancer?
Knowledge-focused CompletedThis study looks back at tissue samples from patients with nasopharyngeal carcinoma who took part in an earlier treatment trial. Researchers are using advanced genetic testing and protein analysis to look for markers linked to how long patients survive. The goal is to better unde…
Sponsor: Hellenic Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Cancer clot care under the microscope: new study mines data for better treatment insights
Knowledge-focused CompletedThis study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Can standard cancer treatment wake up the immune system? a study investigates.
Knowledge-focused CompletedThis study looks at how anti-tumor T-cell responses change in people with lung or head-and-neck cancer who are receiving radiochemotherapy. Researchers will collect blood and tumor samples to track immune markers. The goal is to understand whether this standard treatment can boos…
Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Muscle loss linked to immunotherapy response in lung cancer
Knowledge-focused CompletedThis study looked at 115 adults with advanced non-small cell lung cancer to see if muscle loss (sarcopenia) and a blood-based score called CTI affect how well immunotherapy works. Researchers reviewed medical records to measure muscle on CT scans and calculate CTI from routine bl…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Why does lung cancer come back? new study hunts for genetic clues
Knowledge-focused CompletedThis study is for people with early-stage lung cancer whose cancer returned after taking the drug osimertinib. Researchers will analyze tumor or blood samples to find gene changes linked to the recurrence. The goal is to better understand why some cancers come back, which could h…
Sponsor: Hunan Province Tumor Hospital • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
ECMO in kids with cancer: a closer look at survival and risks
Knowledge-focused CompletedThis study examines how children under 18 with cancer or a history of a stem cell transplant do when they need a machine called ECMO to help them breathe. Researchers looked at bleeding, infections, and survival rates in children treated at one hospital, and compared survival wit…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
AI reads lung cancer scans to predict survival
Knowledge-focused CompletedThis study explores whether artificial intelligence can predict the stage and survival of non-small cell lung cancer by analyzing CT and PET scans. Researchers will train a deep learning model using existing medical records from 156 patients who had lung cancer surgery. The goal …
Sponsor: Hilkat Fatih Elverdi • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Default option nudge may boost cancer screening in High-Risk groups
Knowledge-focused CompletedThis trial tests whether presenting a cancer screening appointment as a pre-selected default option (opt-out) makes people at high risk for lung or stomach cancer more likely to accept it, compared to a standard opt-in approach. Participants complete an online questionnaire and d…
Sponsor: Harbin Medical University • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Suction or no suction? lung biopsy study seeks better samples
Knowledge-focused CompletedThis study looks at whether using suction during a lung biopsy (EBUS-TBNA) helps get better tissue samples from people with suspected lung cancer that has spread to lymph nodes. Researchers will compare samples taken with and without suction to see which method gives more materia…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New tool aims to boost lung cancer trial enrollment
Knowledge-focused CompletedThis study develops and tests a tool designed to help lung cancer nurses talk to patients about clinical trials. The tool provides information on available trials, communication tips, and practical guidance. Researchers will test it in four UK hospitals to see if it improves nurs…
Sponsor: Oxford Brookes University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New tool aims to boost lung cancer trial enrollment
Knowledge-focused CompletedThis study aims to develop and test a tool that helps lung cancer nurses talk to patients about clinical trials. Only about 8% of lung cancer patients in the UK join trials, and nurses often lack the time or confidence to discuss them. The tool will be tested in four UK hospitals…
Sponsor: Oxford Brookes University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a quick chat with a radiotherapy tech ease cancer patients' anxiety?
Knowledge-focused CompletedThis study looked at whether having a special consultation with a radiotherapy technician (called a manipulator) helps cancer patients feel more informed about their treatment. Researchers enrolled 308 adults with various cancers who were getting radiation therapy. They compared …
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Blood test could reveal how lung cancer evolves during treatment
Knowledge-focused CompletedThis study investigates whether a simple blood test (liquid biopsy) can track how advanced non-small cell lung cancer changes during immunotherapy or targeted therapy. Researchers will analyze tumor DNA circulating in the blood to see if it can predict treatment response and dete…
Sponsor: Geneplus-Beijing Co. Ltd. • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Lung cancer clues found in blood vessels near tumors
Knowledge-focused CompletedThis study looked at 30 people with early-stage non-small cell lung cancer who had surgery. Researchers collected blood from a vein near the tumor and from a regular arm vein to study tiny particles called exosomes. The goal was to see if these particles could help predict whethe…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
40,000 patients studied: does a simpler cancer drug dose work just as well?
Knowledge-focused CompletedThis completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Digital platform and DNA analysis aim to personalize lung cancer care
Knowledge-focused CompletedThis completed study in Greece enrolled 200 people with stage 4 non-small cell lung cancer. Researchers used genetic testing to map each tumor's unique features and gave half the patients access to a digital platform to report side effects. The goal was to see if combining person…
Sponsor: Hellenic Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lung cancer radiation: new study tracks breathing side effects
Knowledge-focused CompletedThis study followed 39 lung cancer patients who received radiation therapy to see how it affected their breathing. Researchers measured lung volume and gas exchange capacity before and after treatment, looking for a 20% or greater drop in diffusion capacity at 3 months. The goal …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Hidden roadmaps in the lungs: study maps artery twists to aid cancer surgery
Knowledge-focused CompletedThis completed study looked at 44 patients who had lung cancer surgery to understand how the arteries in the lungs can vary from person to person. Using CT scans and 3D models, researchers mapped these variations to help surgeons avoid complications during lobectomy. The goal was…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Blood test may spot lingering lung cancer after surgery
Knowledge-focused CompletedThis study looked at whether a blood test measuring DNA fragments can detect leftover cancer after lung cancer surgery. Researchers followed 133 patients with early-stage lung cancer for one year after their operation. The goal was to see if changes in the DNA test could predict …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Ultrasound could reveal hidden lung changes after surgery
Knowledge-focused CompletedThis study uses lung ultrasound to measure how the lungs change after surgery to remove part of a lung due to cancer. Researchers will check lung aeration before surgery, right after, and 24 hours later in about 32 adults. They aim to see if ultrasound findings relate to oxygen l…
Sponsor: Ana Broseta Lleó • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could your family tree predict lung cancer risk?
Knowledge-focused CompletedThis completed study enrolled 336 people with non-small cell lung cancer to collect detailed family cancer histories using a questionnaire. Researchers want to see if certain patterns of cancer in relatives, along with smoking and other risk factors, can help identify patients wh…
Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists explore GLUT1 protein as a diagnostic clue for rare lung tumors
Knowledge-focused CompletedThis study tested whether a protein called GLUT1 could help doctors better classify lung neuroendocrine tumors. Researchers analyzed tumor samples from 36 patients to see if GLUT1 staining patterns matched tumor type. The goal was to find a more reliable diagnostic tool than curr…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may spot hidden infections in lung cancer patients
Knowledge-focused CompletedThis study looked at whether measuring procalcitonin (PCT) levels in the blood could help detect infections earlier in people with stage IV non-small cell lung cancer starting chemotherapy. Researchers enrolled 45 patients and took a PCT blood sample before their first chemo sess…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Lung cancer Patients' sleep troubles under the microscope
Knowledge-focused CompletedThis study explored sleep disorders in 37 adults with non-small cell lung cancer. Participants filled out questionnaires about their sleep, symptoms, mood, and quality of life. The goal was to create a guide to help doctors diagnose and treat sleep issues in this group, ultimatel…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Can bone markers predict survival in lung cancer patients?
Knowledge-focused CompletedThis study enrolled 200 adults with lung adenocarcinoma that has spread to the bones. Researchers took bone biopsies, scans, and blood tests to measure bone and metabolic markers. The goal is to see if these markers are linked to how long patients live. This is an observational s…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Smartphones track lung cancer patients' steps during radiation
Knowledge-focused CompletedThis study looked at how physically active lung cancer patients are during radiation therapy. Twenty adults with lung cancer carried smartphones that counted their steps. Researchers compared step counts from the first week of treatment to the fifth week to see if activity change…
Sponsor: University Hospital Schleswig-Holstein • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New 4D scan could sharpen lung cancer radiation
Knowledge-focused CompletedThis study tested whether a special 4D PET-CT scan can help doctors better target radiation for lung cancer. Seven patients with non-small cell lung cancer received both a standard CT scan and a 4D PET-CT scan before radiotherapy. Researchers compared the tumor volumes identified…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New approach to CPR talks may help patients and families feel heard
Knowledge-focused CompletedThis study tested a new way for doctors to discuss CPR with older, seriously ill patients and their families. Instead of the usual conversation, doctors followed a step-by-step guide that focused on the patient's values and explained why CPR might not help. The goal was to see if…
Phase 2/3 • Sponsor: University of Vermont • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Real-World data reveals how lung cancer patients fare on Triple-Drug combo
Knowledge-focused CompletedThis study looked at 302 patients with advanced non-small cell lung cancer in Greece who were treated with a combination of nivolumab, ipilimumab, and chemotherapy as their first therapy. Researchers tracked patient characteristics, treatment patterns, and survival rates over tim…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Scientists collect chest tumor samples to unlock secrets of cancer spread
Knowledge-focused CompletedThis study collected tissue and blood samples from 143 people with malignant pleural effusion (cancer that has spread to the lining of the chest). The goal was to create a biobank for future research into why cancer cells in the chest may differ from the original tumor. No treatm…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New study aims to fix lack of diversity in cancer trials
Knowledge-focused CompletedThis completed study looked at ways to increase diversity in cancer clinical trials, focusing on breast, liver, and prostate cancers. Researchers worked with communities, doctors, and scientists in New York City to find better ways to include people of color and underserved group…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Simple urine test could show if lung cancer immunotherapy is working
Knowledge-focused CompletedThis completed study looked at 150 people with advanced non-small cell lung cancer to see if proteins and metabolites in blood and urine could help monitor how well immunotherapy is working. Researchers used mass spectrometry to measure these markers before, during, and after tre…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Breathing machine tweak may help oxygen during lung surgery
Knowledge-focused CompletedThis study looked at how to best set a breathing machine during lung surgery when only one lung is being used. The goal was to see if using smaller breaths with higher pressure could keep oxygen levels stable. 88 adults having lung surgery took part. The study measured oxygen in …
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Lung doctors take on lab role: can they match pathologists?
Knowledge-focused CompletedThis study looked at whether a lung specialist (pulmonologist) can quickly check biopsy samples during a lung cancer procedure, a job usually done by a pathologist. Researchers compared the pulmonologist's on-the-spot assessment with the pathologist's final report in 189 patients…
Sponsor: Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Can a phone app keep lung cancer patients moving during treatment?
Knowledge-focused CompletedThis study tested a smartphone app that reminds people to walk several times a day. It was designed to help lung cancer patients stay active during radiotherapy. Thirty healthy volunteers downloaded the app and rated how easy it was to use. The goal was to see if the app is user-…
Sponsor: University Hospital Schleswig-Holstein • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Dye vs. air: which better guides lung cancer surgery?
Knowledge-focused CompletedThis study compared two ways for surgeons to see the borders between lung segments during surgery for early-stage non-small cell lung cancer. One method uses a green dye and a special camera, the other uses a modified inflation-deflation technique. The trial involved 272 patients…
Sponsor: The First Affiliated Hospital of Nanchang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Joint pain from cancer drug measured in new study
Knowledge-focused CompletedThis completed study looked at how often joint pain occurs in 71 people with ovarian, colorectal, or lung cancer who were taking the drug bevacizumab. Participants filled out a questionnaire about their joint pain over 6 months. The goal was to better understand this side effect.
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Lung cancer trial targets tumor diversity to outsmart resistance
Knowledge-focused CompletedThis phase 2 trial studied 50 people with non-small cell lung cancer to see if differences within a tumor (called heterogeneity) affect how well treatments work. Patients received one of four drugs based on their tumor's genetic changes: atezolizumab (immunotherapy), vemurafenib,…
Phase 2 • Sponsor: University College, London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
AI analyzes 10,000 patient records to predict head and neck cancer recurrence
Knowledge-focused CompletedThis completed study used artificial intelligence to examine electronic health records from 10,000 head and neck cancer patients. The goal was to create models that can predict the risk of cancer coming back or progressing, and to identify which patients might live longer after i…
Sponsor: Savana Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Lung cancer study reveals hidden toll of muscle loss during targeted therapy
Knowledge-focused CompletedThis study looked at the nutrition and body composition of 25 adults with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured weight, muscle mass, and strength to see how common malnutrition and muscle loss were, and how these affected quality of…
Sponsor: Fundacin Biomedica Galicia Sur • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for clues to why immunotherapy fails in most patients
Knowledge-focused CompletedThis study looked at 135 people with advanced lung cancer, lymphoma, or other tumors treated with immunotherapy drugs called checkpoint inhibitors. Researchers collected blood and tumor samples over time to measure immune cells and molecules that might predict whether the treatme…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Which treatment saves your voice better? surgery vs. radiation for early throat cancer
Knowledge-focused CompletedThis study looked at 41 people who had early-stage vocal cord cancer and were treated with either surgery or radiation. The goal was to see which treatment led to better voice quality five years later. Patients filled out a questionnaire about their voice, and doctors also measur…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
1200 lung biopsies analyzed: how often do complications occur?
Knowledge-focused CompletedThis completed study looked at 1200 patients who had a CT-guided needle biopsy of a lung nodule at St. Olavs Hospital between 2012 and 2023. The goal was to track how often complications like a collapsed lung (pneumothorax), lung bleeding, or air embolism happen. By analyzing the…
Sponsor: St. Olavs Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Can a pacemaker for the diaphragm save more donor lungs?
Knowledge-focused CompletedThis small study tested a device that paces the diaphragm in brain dead organ donors whose lungs were too damaged for transplant. The goal was to see if this approach could improve lung function enough to make the lungs usable. Only 3 people took part, so the results are very ear…
Sponsor: Fraser Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Free 3D lung maps could make surgery safer
Knowledge-focused CompletedThis study tested whether free, open-source software can create 3D models of the lungs to help surgeons during lung cancer surgery. 13 patients scheduled for lung surgery had their CT scans turned into 3D reconstructions. The goal was to see if these models were easy for surgeons…
Sponsor: Erik de Loos • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Free rides and scheduling help may boost lung cancer screening rates
Knowledge-focused CompletedThis completed study tested whether offering free transportation and help scheduling appointments could improve attendance at lung cancer screenings in Philadelphia. Over 250 residents with upcoming or missed low-dose CT scans were offered these services. The goal was to see if s…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Pharmacist Check-Ins may cut cancer Patients' emergency trips
Knowledge-focused CompletedThis study tested whether a hospital pharmacist's interview could reduce unplanned doctor visits or hospital stays for adults with lung cancer receiving chemotherapy, immunotherapy, or oral targeted therapy. Researchers tracked 60 patients over six months, counting unscheduled co…
Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Blood test tracks lung cancer resistance in Real-World study
Knowledge-focused CompletedThis study looked at whether a simple blood test (liquid biopsy) can detect a specific resistance mutation called T790M in patients with advanced non-small cell lung cancer whose tumors stopped responding to initial targeted therapy. Researchers followed 70 patients in Tunisia, c…
Sponsor: Faculty of Medicine of Tunis • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Study reveals smoking and drinking habits after cancer diagnosis
Knowledge-focused CompletedThis study looked at 385 adults diagnosed with their first lung or head & neck cancer to see how many continued using tobacco or alcohol over the next year. Researchers tracked smoking and drinking habits, as well as how long patients lived without the cancer getting worse. The g…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Lung cancer protein study may unlock new clues
Knowledge-focused CompletedThis study examined pieces of the Met receptor protein in tumor and healthy tissue from 56 people with non-small cell lung cancer. Researchers used blood and tissue samples taken during surgery or biopsy to see which Met fragments are present and whether they are active. The goal…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Regional lung cancer database aims to link mutations to patient outcomes
Knowledge-focused CompletedThis study created a detailed database of 518 adults with non-small cell lung cancer in the Nord Pas de Calais region of France. Researchers collected clinical information and genetic mutation data to see how factors like age, smoking, and cancer stage relate to specific mutation…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Lung cancer study reveals Real-World treatment patterns
Knowledge-focused CompletedThis study looked back at the medical records of 833 people with advanced non-small cell lung cancer to understand how they were treated and how long they lived. Researchers collected information from doctors' surveys across multiple countries. The goal was to learn about real-wo…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Can a simple survey improve End-of-Life conversations for cancer patients?
Knowledge-focused CompletedThis pilot study tested whether a short survey can help hospitalized patients with advanced lung or gastrointestinal cancers discuss their goals and preferences with their oncologist after leaving the hospital. The survey asks about treatment goals and understanding of the diseas…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New program aims to catch lung cancer early by boosting screening rates
Knowledge-focused CompletedThis study tested a program to help more people at high risk for lung cancer get a low-dose CT scan, which can catch the disease early and save lives. The program included notifying doctors, educating patients, offering financial help, and reminding patients to talk about screeni…
Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New study tackles bone pain caused by chemo-boosting drug
Knowledge-focused CompletedThis study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Lung cancer & COVID: new study tracks immune response in nearly 2,000 patients
Knowledge-focused CompletedThis study looked at nearly 2,000 adults with lung cancer who caught COVID-19. Researchers tracked their health and checked for antibodies (immune system markers) right after infection and again 6 months after vaccination. The goal was to understand how lung cancer affects the bo…
Sponsor: Fundación GECP • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Breath test breakthrough: scientists read RNA in exhaled air
Knowledge-focused CompletedThis pilot study tested whether it is possible to collect and analyze small RNA molecules from a person's breath. Researchers took breath samples from 25 volunteers (healthy people and a few with lung disease) at rest and after intense exercise. They successfully extracted and se…
Sponsor: Medical University of Bialystok • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Lung cancer study sheds light on hidden sexual struggles
Knowledge-focused CompletedThis study looked at sexual problems in 553 adults with lung cancer. Researchers wanted to find out how common these issues are and how severe they can be. The goal is to help doctors better support patients during and after cancer treatment.
Sponsor: Fundación GECP • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Timing is everything: could your body clock influence lung cancer?
Knowledge-focused CompletedThis study looked at whether the time of day affects the number of cancer cells in the blood of people with advanced lung cancer. Researchers took blood samples from 27 patients at 4 a.m. and 10 a.m. before starting treatment. The goal was to see if circadian rhythms influence ho…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Rural cancer care boost: virtual training aims to close Follow-Up gaps
Knowledge-focused CompletedThis study tested a program called KanSurvive, which uses virtual education sessions and practice support to help rural primary care clinics improve follow-up care for cancer survivors. Researchers worked with 15 rural practices to see if they could better follow guidelines for m…
Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists track Body's reaction to cancer immunotherapy
Knowledge-focused CompletedThis study looked at 98 adults with cancers like melanoma and lung cancer who were starting immunotherapy. Researchers measured inflammatory markers in their blood to understand how the body reacts to these drugs. The goal was to find ways to better manage side effects from treat…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New scanner aims to sharpen cancer radiation accuracy
Knowledge-focused CompletedThis study tested a new cone-beam CT scanner designed to take clearer images while patients are on the radiotherapy couch. 41 adults with head-and-neck, lung, breast, abdominal, or pelvic cancer each had one or two scans with the new device. The goal was to see if the images were…
Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Can a simple scan predict lung cancer treatment success?
Knowledge-focused CompletedThis study looked at 40 people with advanced non-small cell lung cancer who were starting treatment with the drug pembrolizumab. Researchers used special PET scans after each of the first three doses to see how the cancer's metabolism changed. The goal was to find out if early sc…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New imaging technique may spot lung cancer recurrence sooner
Knowledge-focused CompletedThis study looked at whether a special type of PET scan called parametric imaging can better predict if lung cancer will come back within a year after chemoradiation. Researchers compared it to standard PET scans in 40 patients with non-small cell lung cancer. The goal is to see …
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New test may predict lung cancer treatment success
Knowledge-focused CompletedThis study tested whether a combination of 6 markers from tumor tissue could predict how well patients with advanced non-small cell lung cancer respond to first-line treatment with pembrolizumab (immunotherapy) plus chemotherapy. Researchers analyzed tissue samples from 106 patie…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Chemo nausea still a problem despite standard care, study finds
Knowledge-focused CompletedThis study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Cancer patients speak out: what they really want from pharmacy visits
Knowledge-focused CompletedThis study asked 167 people with cancer (and their caregivers) what they value most during pharmacy consultations for oral cancer drugs. Using a survey method, researchers identified key preferences to help hospitals design better support services. The goal was to improve patient…
Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Simple blood test may reveal early if lung cancer therapy works
Knowledge-focused CompletedThis study looked at 100 people with advanced non-small cell lung cancer to see if changes in tumor DNA in the blood (ctDNA) can predict how well treatment is working. Researchers took blood samples before treatment, at 3 weeks, and at 9 weeks. The goal was to see if a rise or fa…
Sponsor: Centre Hospitalier Departemental Vendee • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
535 lung cancer patients studied to see how nivolumab performs after chemo
Knowledge-focused CompletedThis study looked at 535 people in France with advanced non-small cell lung cancer who were given nivolumab after at least one round of chemotherapy. Researchers wanted to see how well the drug worked, how long it kept cancer from getting worse, and what side effects occurred in …
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Real-World check: Nivolumab's survival impact on lung cancer patients
Knowledge-focused CompletedThis study looked at 212 adults with advanced non-small cell lung cancer who received the drug nivolumab after chemotherapy. Researchers tracked how many patients were still alive 12, 24, and 36 months after starting treatment. The goal was to see how well the drug works in every…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Chicken eggs used to grow patient cancer cells in new automated system
Knowledge-focused CompletedThis study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Telling the truth about chemo may improve End-of-Life care
Knowledge-focused CompletedThis study looked at whether explaining the risks of chemotherapy more honestly to patients with incurable lung cancer could reduce the number who receive chemo in their last month of life. Researchers randomly assigned 123 patients to either standard information or a more detail…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Imfinzi under the microscope: how does it perform outside the lab?
Knowledge-focused CompletedThis study tracked over 700 people in Korea who were already receiving the cancer drug Imfinzi (durvalumab) for lung or biliary tract cancer. The goal was to see how safe and effective the drug is in everyday medical practice, not just in strict clinical trials. Researchers monit…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Massive tumor study counts rare gene fusions
Knowledge-focused CompletedThis completed study examined tumor samples from 3820 people with advanced solid tumors to find how many have NTRK gene fusions. Researchers used genetic testing to identify these rare changes. The study did not test any treatment, but aims to guide future targeted therapy decisi…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Liver health may change how lung cancer drug works
Knowledge-focused CompletedThis study looked at how the drug JDQ443 behaves in people with different levels of liver function. It included 33 adults with small cell lung cancer and mild, moderate, or severe liver problems, plus healthy volunteers. The goal was to measure drug levels in the blood to guide s…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
French study checks if new combo works for mesothelioma in everyday practice
Knowledge-focused CompletedThis study looks back at 204 patients with untreated, inoperable malignant pleural mesothelioma who received a combination of two immunotherapy drugs, nivolumab and ipilimumab, through an early access program in France. Researchers will collect data from medical records to see ho…
Sponsor: Groupe Francais De Pneumo-Cancerologie • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Study tracks swallowing troubles in head and neck cancer patients for 18 months
Knowledge-focused CompletedThis study followed 240 people with head and neck cancer to see how their swallowing changed from diagnosis to 18 months after their first treatment. Researchers used a questionnaire called the Deglutition Handicap Index (DHI) to measure patients' own experience of swallowing pro…
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
New study links smoking and alcohol to worse cancer outcomes
Knowledge-focused CompletedThis completed study looked at 165 adults newly diagnosed with lung or head & neck cancer who smoked. Researchers interviewed them by phone about their smoking and drinking habits, and followed up at 3, 6, and 12 months. The goal was to understand what makes it harder or easier f…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Blood test reveals why lung cancer drugs stop working
Knowledge-focused CompletedThis study looked at 62 people with ALK-positive lung cancer whose tumors had stopped responding to newer targeted drugs. Instead of a tissue biopsy, researchers used a blood test (liquid biopsy) to find genetic changes that cause resistance. The goal was to better understand the…
Sponsor: Addario Lung Cancer Medical Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Can tracking lung nodules save lives? new study maps care in latin america
Knowledge-focused CompletedThis completed study looked at how lung nodules are found and managed in hospitals across Latin America. Researchers tracked 562 adults to see how long it takes from finding a nodule to getting a diagnosis and treatment. The goal is to understand current practices and find ways t…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Your voice matters: study tests if patient symptom reports help doctors catch side effects earlier
Knowledge-focused CompletedThis study looked at whether having cancer patients report their own symptoms during radiation treatment helps doctors notice and manage side effects better. About 104 adults with lung, esophageal, or other gastrointestinal cancers took part. Doctors reviewed patient-reported sym…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Lung cancer Treatment's hidden toll on physical strength revealed
Knowledge-focused CompletedThis completed study followed 150 lung cancer patients to see how their treatment—surgery, chemo, radiation, or immunotherapy—affects their physical abilities, symptoms, and quality of life. Researchers measured things like walking distance, muscle strength, and daily activity le…
Sponsor: Hasselt University • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:56 UTC
-
Home infusions for lung cancer: a small study tests feasibility
Knowledge-focused CompletedThis study looked at whether immunotherapy for bronchial (lung) cancer can be given at home instead of in a hospital. Ten patients who were already stable on treatment received their infusions at home. Researchers tracked how many had to stop home care for medical reasons, monito…
Sponsor: RENAULT Patrick Aldo • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:47 UTC
-
Lung cancer gene map after drug failure could guide next steps
Knowledge-focused CompletedThis completed study looked at gene changes in 182 people with advanced lung cancer whose disease got worse after first-line treatment with Osimertinib. Researchers collected tissue and blood samples to understand why the drug stopped working. The goal is to use this information …
Phase 4 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:56 UTC
-
New french survey aims to better understand swallowing after throat cancer surgery
Knowledge-focused CompletedThis completed study tested a French version of a swallowing questionnaire for people who had their throat and voice box removed due to cancer. Researchers wanted to see if the translated survey works well for French-speaking patients. The study involved 225 adults who could read…
Sponsor: Centre Hospitalier de Valence • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:30 UTC
-
New lung nodule marking method could replace CT-Guided technique
Knowledge-focused CompletedThis completed trial with 66 participants compared two methods for marking small lung nodules before minimally invasive surgery: navigational bronchoscopy using a green dye (ICG) and CT-guided radioisotope injection. The goal was to see which method helps surgeons find and remove…
Sponsor: Semmelweis University • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:12 UTC
-
Free transport boosts lung cancer screening attendance in west philadelphia
Knowledge-focused CompletedThis study tested a community support program that offered free transportation to lung cancer screening appointments for West Philadelphia residents. Out of 242 participants, researchers measured how many people attended their scheduled low-dose CT scans. The goal was to see if r…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:04 UTC
-
New 3D map may help surgeons remove lung cancer more accurately
Knowledge-focused CompletedThis study tested a software tool called RUS Lung that creates a 3D model of a patient's lungs from CT scans. Surgeons used it to plan and guide minimally invasive surgery for early-stage lung cancer. The study enrolled 34 adults and checked how well the tool matched the actual t…
Sponsor: Hutom Corp • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:54 UTC